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Abstract 
Huntington’s disease (HD) is a fatal autosomal dominant neurodegenerative disease. HD 
has no cure, and patients pass away 10-20 years after the onset of symptoms. The causal 
mutation for HD is a trinucleotide repeat expansion in exon 1 of the huntingtin gene that 
leads to a polyglutamine (polyQ) repeat expansion in the N-terminal region of the 
huntingtin protein. Interestingly, there is a threshold of 37 polyQ repeats under which little 
or no disease exists, and above which, patients invariably show symptoms of HD. The 
huntingtin protein is a 350 kDa protein with unclear function. As the polyQ stretch 
expands, its propensity to aggregate increases with polyQ length. Models for polyQ 
toxicity include formation of aggregates that recruit and sequester essential cellular 
proteins, or altered function, producing improper interactions between mutant huntingtin 
and other proteins. In both models, soluble expanded polyQ may be an intermediate 
state that can be targeted by potential therapeutics. In the first study described herein, 
the conformation of soluble, expanded polyQ was determined to be linear and extended 
using equilibrium gel filtration and small-angle X-ray scattering. While attempts to purify 
and crystallize domains of the huntingtin protein were unsuccessful, the aggregation of 
huntingtin exon 1 was investigated using other biochemical techniques including 
dynamic light scattering, turbidity analysis, Congo red staining, and thioflavin T 
fluorescence. Chapter 4 describes crystallization experiments sent to the International 
Space Station and determination of the X-ray crystal structure of the anti-polyQ Fab 
MW1. In the final study, multimeric fibronectin type III (FN3) domain proteins were 
engineered to bind with high avidity to expanded polyQ tracts in mutant huntingtin exon 
1. Surface plasmon resonance was used to observe binding of monomeric and 
multimeric FN3 proteins with huntingtin.  
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Chapter 1: Huntingtin 
1. Huntington’s Disease 
Huntington’s disease (HD) is a fatal neurodegenerative disease in humans that is 
caused by an expanded trinucleotide repeat (CAG)n in the huntingtin gene on 
chromosome 4p16.3 [1], in the first exon of the huntingtin gene. The encoded huntingtin 
protein has a series of repeated glutamine amino acid residues known as a 
polyglutamine (polyQ) repeat. The pathogenic mechanism of HD is thought to involve a 
conformational transition that occurs in expanded polyQ tracts (>37 glutamines) that 
leads to formation of toxic aggregates, although the nature of this conformational 
transition is unclear. Despite knowledge of the causal mutation, there is currently no 
effective treatment to delay or prevent HD onset or progression. 
 
1.1 Genetics 
The first exon of the huntingtin gene contains a repetitive DNA stretch of three repeated 
nucleotides: C (cytosine), A (adenine), and G (guanine). In normal individuals, this 
stretch of trinucleotides consists of 18 to 22 CAG repeats. When 36-39 CAG repeats are 
present, HD occurs in some, but not all, people [2], known as ‘variable penetrance.’ 
When the CAG repeat length expands to more than 39 CAG repeats, HD is observed in 
100% of patients, known as ‘complete penetrance.’ While the normal CAG repeat is 
stably inherited, longer CAG repeats change in length when transmitted to subsequent 
generations. Large increases in CAG repeat length are sometimes seen with paternal 
transmission of mutant huntingtin, resulting in an earlier age of onset of the disease, 
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known as ‘anticipation’ [3]. 
The severity of the disease and the younger age at which the onset of Huntington’s 
disease occurs are correlated positively with the length of the CAG repeat [4]; the longer 
the CAG repeat, the earlier in life patients begin to exhibit HD symptoms. Although age 
of onset of HD can be predicted by CAG length, CAG length only accounts for half of the 
variation in age of onset, with the remaining variance attributable to other genes and 
environmental factors [4]. Several genes involved in DNA repair mechanisms, including 
MLH1, have recently been shown to modify the age of onset of HD by several years [5]. 
Most patients with HD have repeat lengths of 40 to 50 CAG, and onset of symptoms 
typically occurs in the fourth or fifth decade of life [6]. When the CAG tract expands to 
>62 repeats, onset of HD occurs in the first or second decade of life with symptoms 
distinct from adult-onset HD, and is known as ‘juvenile HD’ [7]. Because onset of juvenile 
HD occurs prior to reproductive age, the longest mutations are not passed down to the 
next generation. On average, patients die 17 years after symptoms begin [8], regardless 
of polyQ length or age of onset (Marcy MacDonald, personal communication, May 10, 
2015). 
HD is an autosomal dominant disorder, so there is a 50% chance of passing the HD 
mutation from parent to offspring, regardless of gender. Intriguingly, individuals with two 
copies of the HD disease gene have the same age of HD onset and severity as 
individuals with only one mutated copy, which is unique among autosomal dominant 
disorders. 
HD has an estimated prevalence of 2.7 per 100,000 people worldwide, and 5.7 per 
100,000 people in North America, with a higher prevalence in populations with European 
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heritage [9, 10]. At least 30% of HD chromosomes appear to be ancestrally related [1]. 
The Maracaibo region of Venezuela has one of the highest prevalences of HD in the 
world at 700 in 100,000 people, which is thought to be due to Spanish colonization of 
Venezuela in the 16th century [10]. Using polymorphic DNA markers of families in 
Venezuela with HD, the genetic defect was mapped to chromosome 4 [11]. Several 
years later, the (CAG)n repeat expansion was mapped to the IT15 gene [1], later 
renamed huntingtin. 
 
1.2 Clinical Presentation 
Patients with HD suffer from a triad of clinical findings: 1) movement disorders including 
chorea, dystonia, and lack of coordination; 2) cognitive deficiencies such as impaired 
executive function and memory; and 3) psychiatric and behavioral symptoms. Chorea is 
derived from the Greek word for “dance” (with the same root as choreography) [12], and 
is characterized by short, involuntary movements that increase in frequency and severity 
during the progression of HD in many patients. The symptoms of HD are correlated with 
progressive neuron loss in the brain, particularly in medium spiny neurons in the basal 
ganglia, caudate nucleus, and putamen [13]. These areas of the brain are important in 
control of motor movements and behavior, and damage to these areas is thought to lead 
to the characteristic symptoms of HD. 
HD is diagnosed by family history and genetic testing. Testing of individuals suspected 
of inheriting the CAG mutation in the huntingtin gene is rarely performed in individuals 
less than 18 years old due to ethical concerns [7].  
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The course of HD is divided into several stages. In the first stage, patients have minor 
symptoms, and they are able to live and function with minor accommodations. In the 
middle stages of HD, patients often are unable to drive and may begin to have significant 
motor difficulties, such as falls and trouble swallowing, but can perform some functions 
with assistance. In late-stage HD, patients require 24-hour care, and have significant 
communication difficulties. 
While the onset of HD symptoms typically occurs during adulthood, 6% of HD patients 
have symptoms before the age of 20. In contrast with adult HD patients, patients with 
juvenile HD exhibit tremor and sustained involuntary muscle contractions instead of 
chorea [7]. 
Monitoring symptoms of patients in a clinical setting is difficult, and few tests exist to 
judge neural health. The Unified Huntington’s Disease Rating Scale (UHDRS) [14-16] 
has been used for the last 20 years to evaluate patients with HD. Tests include an 
assessment of motor skills, including ocular pursuit, finger taps, and gait appraisal; 
cognitive assessment, including verbal fluency and word reading; behavioral 
assessment, with questions to judge the frequency and severity of the patients’ behavior, 
suicidal thoughts, depression, hallucinations, and other behaviors associated with HD. 
Also included in the UHDRS is an assessment of the independence and functional 
capacity of the patient throughout disease progression. 
While many clinical trials for potential HD therapeutics have relied on the UHDRS for 
patient evaluation, several new, less subjective tests have been developed in the past 
five years that directly monitor CSF concentration of huntingtin. The first of these tests is 
a Forster resonance energy transfer (FRET) assay [17, 18], in which two labeled 
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monoclonal antibodies directed against huntingtin N-terminal epitopes are bound to 
huntingtin. Aggregates of mutant huntingtin are recognized preferentially by this antibody 
pair, and the donor and acceptor fluorophores are able to generate a FRET signal. The 
second assay uses a micro-bead based immunoprecipitation and flow cytometry (IP-
FCM) [19], using similar antibodies as the FRET assay. While these tests are still under 
clinical evaluation, it is hoped that they will improve assessment of HD progression as 
well as more clearly delineate treatment efficacy. 
1.3 Treatment 
Several medications are prescribed for patients with HD, including antidepressants, 
sedatives, and botulinum toxin injection for treating dystonia [20]. Because HD is a 
progressive disease, medications must be evaluated on a regular basis. Education, 
exercise, and diet are also important parts of management of HD. 
Only one drug, tetrabenazine (Xenazine®), is approved for treatment of Huntington’s 
Disease [21]. Tetrabenazine was approved in 2008 for treatment of chorea, and while it is 
effective at reducing chorea in patients with HD by decreasing dopamine release, it also 
can cause sedation and depression, problems for which patients with HD are already at 
elevated risk. All other drugs have failed in clinical trials. 
It is possible that previous clinical trials have been unsuccessful due to a focus on single 
pathways that mutant huntingtin affects, while mutant huntingtin affects a large number of 
integrated pathways. Therefore, changing the level of mutant huntingtin protein expression 
may be a more comprehensive method of treating HD. Methods to decrease the amount 
of huntingtin protein include intrabodies [22-24] and gene silencing techniques such as 
single-stranded RNAs (RNAi) [25] and antisense oligonucleotides (ASO) [26, 27] that 
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target either the polyQ stretch or disease-linked polymorphisms. Several observational 
trials of HD, including PREDICT-HD, Registry, ENROLL-HD, and COHORT [20], are 
helping to prepare for upcoming gene silencing clinical trials. 
 
2. Huntingtin function 
Huntingtin is a 3,144-amino-acid protein with a molecular mass of 348 kDa. However, 
the role of wild-type huntingtin is poorly understood. Huntingtin is expressed in the 
cytoplasm of all human and mammalian cells, with the highest concentrations found in 
the brain and the testes. In neurons and fibroblasts, huntingtin has also been found in 
the nucleus [28, 29]. The first exon of huntingtin, which contains the disease-causing 
CAG repeat in humans, is highly conserved across all mammals. In mice, huntingtin has 
an 86% sequence identity with human huntingtin DNA and a 91% sequence identity with 
human huntingtin protein [30]. However, the murine gene has a CAG repeat that 
encodes only 7 consecutive glutamines, which explains the lack of a natural mouse 
model of HD. In addition to mammals, zebrafish, drosophila, and slime molds also have 
orthologs of huntingtin, suggesting that huntingtin is required for some basic cellular 
function. A series of mouse studies has shown that huntingtin is essential early in 
embryonic development, even before the emergence of the nervous system, and that it 
may also play an important role in basal ganglia function during adulthood. When the 
murine homolog of huntingtin was inactivated, Hd -/- homozygous embryos died soon 
after gastrulation, while heterozygotes had increased levels of motor activity and 
“cognitive deficits” [31]. Interestingly, physical disruption or deletion of portions of the 
huntingtin gene in humans does not cause HD, suggesting that the mutant huntingtin 
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gene may give the huntingtin protein a toxic gain of function. One study reported that the 
polyQ tract in huntingtin was an important regulator of mitochondrial ADP-
phosphorylation in both non-HD and HD CAG repeat ranges [32]; however, many other 
functions for huntingtin have been proposed, including cytoskeletal anchoring and 
facilitation of signal transduction. 
While HD is the most common inherited neurodegenerative disease, nine other human 
diseases in addition to HD are caused by expressed, expanded polyQ repeats. These 
diseases include spinocerebellar ataxia types 1, 2, 3, 6, 7, 12, and 17, 
detatorubropallidoluysian atrophy, and spinobulbar muscular atrophy. In each of these 
diseases, there is selective neurodegeneration, and neurons can be found with 
inclusions containing aggregated polyglutamine proteins. Additionally, for each of these 
disorders, irrespective of the protein affected, the length of the polyQ repeat inversely 
correlates with the age of onset and directly correlates with disease severity, with the 
longest polyQ repeats associated with early-onset (juvenile) forms of the disease. 
Interestingly, several of these disorders have similar polyQ repeat ranges to HD, with 
disease onset occurring after expansion to ≥ 35-40 polyQ repeats. This range may be 
affected by the location of the polyQ repeat within the expressed protein or other 
properties of the affected protein. 
 
3. Huntington Aggregation 
Although the precise role of the polyQ stretch within huntingtin in the pathology of 
Huntington’s disease is uncertain, this abnormal region of huntingtin is presumed to 
cause excessive protein binding interactions with other cellular proteins or with other 
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polyQ repeats. These excessive interactions result in the formation of large, insoluble, 
inactive protein aggregates in affected brain regions called inclusions. In vitro, polyQ 
repeats containing least 37 glutamines aggregate, forming dimers, trimers, and higher-
order oligomers. The rate of aggregation is faster with increasing numbers of glutamine 
residues, which seems to explain the correlation between disease severity and polyQ 
repeat length. 
The exact mechanism whereby polyQ aggregation leads to neurotoxicity in HD has not 
yet been determined. However, several important processes leading to 
neurodegeneration have been elucidated. Mutant huntingtin has a higher proteolysis rate 
than wild-type huntingtin. Truncated huntingtin causes increased aggregates and may 
translocate to the nucleus [8]. Mutant huntingtin may harm neurons through cell-cell 
interactions by disrupting the function of nearby neurons or glia that support that neuron. 
Aggregates also may interfere with normal proteins by recruiting normal interaction 
partners of wild-type huntingtin into their aggregate matrix. At some point, the aggregate 
formation overcomes the cells’ ability to degrade them, leading to inclusion bodies and 
neuron death. However, the toxicity of aggregated huntingtin has been intensely debated 
due to conflicting evidence that the aggregates are harmful, neutral, or neuroprotective. 
Infrared microspectroscopy was used to demonstrate that huntingtin inclusions in brains 
of patients with HD are, in fact, polymorphic; beta-sheet conformations appeared to be 
highly neurotoxic, while other inclusions that lacked structural rearrangements appeared 
to be non-toxic [33]. One recent study found that proteins with disordered domains are 
recruited to polyQ aggregates, including many RNA-binding proteins [34], which could 
account for toxicity independent of the function of the polyQ stretch. Other studies have 
suggested that mutant huntingtin spreads through the CSF with prion-like propagation, 
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where the small nuclei of mutant huntingtin are able to seed aggregation of monomeric 
mutant huntingtin [35], cascading into a larger effect both intra- and extra-cellularly. 
 
4. Huntington Structure 
4.1. Huntingtin Exon 1 
The protein encoded by exon 1 of the huntingtin gene (hereafter referred to as huntingtin 
exon 1 protein) includes 90 amino acids (for a Q23 reference sequence) and four distinct 
regions. An N-terminal 17-amino-acid region (N17) is located immediately before the 
polyQ region. The polyQ region is followed by a polyproline (polyP) region. Interestingly, 
polyQ stretches >6 glutamines and the polyP region are each found only in mammals 
[36], leading to the hypothesis that the polyP region may help to stabilize the polyQ 
region [37]. C-terminal to the polyP region is a proline-rich region (PRR). 
 
        10         20         30         40         50         60  
MATLEKLMKA FESLKSFQQQ QQQQQQQQQQ QQQQQQQQQQ PPPPPPPPPP PQLPQPPPQA  
 
        70         80         90  
QPLLPQPQPP PPPPPPPPGP AVAEEPLHRP  
 
Fig. 1-1. Amino acid sequence of huntingtin exon 1 protein with 23 glutamines. The N17 
region is shown in blue, polyP region in red, and PRR in green. NCBI Reference 
Sequence: NP_002102.4, huntingtin [Homo sapiens]. 
The N17 region has several post-translational modifications, including phosphorylation, 
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acetylation, and sumoylation, and N17 is proposed to mediate nuclear transport of 
huntingtin and modify the association of huntingtin to with the cytoplasmic membrane. 
Transgenic mice with mutant huntingtin without the N17 domain show increased cellular 
pathology and more overt disease compared with mice with huntingtin containing the 
N17 domain [38]. 
Several partial structures have been solved and deposited into the Protein Data Bank 
repository (www.rcsb.org) (Table 1-1); however, none of the deposited structures contain 
the entire polyQ region thought to be critical for pathogenesis of mutant huntingtin. Two 
NMR solution structures of the first 17 amino acids in the N-terminal domain show that 
the N17 domain can transition between an alpha-helical conformation in micelles to a 
random coil in aqueous solutions [39].  
Six medium- to high-resolution X-ray crystal structures including the N17 domain and 
several glutamines in non-pathologic polyQ stretches of huntingtin were crystallized as 
part of a maltose-binding protein (MPB) fusion protein at 3.5 Å resolution [40] (PDB:3IO4, 
3IO6, 3IOR, 3IOT, 3IOU, 3IOV, 3IOW). In this series of structures, the modeled polyQ 
region was conformationally flexible and was affected by the conformation of nearby 
residues.  
Four additional X-ray crystal structures of huntingtin with a Q36 stretch with 3 histidine 
residues introduced within the polyQ stretch, also as part of a MBP fusion protein [41]. 
While the polyQ region adopts several conformations, the histidine insertions and the 
non-pathogenic polyQ repeat length add uncertainty to any conclusions drawn from this 
structure. 
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STRUCTURE PDB ID RESOLUTION 
Solution structure of the N-terminal domain of huntingtin 
(htt17) in 50% TFE [39] 2LD0 Solution NMR 
Solution structure of the N-terminal domain of huntingtin 
(htt17) in presence of DPC micelles [39] 2LD2 Solution NMR 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C95 [40] 3IOR 2.68 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C92-b [40] 3IOT 2.71 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C94 [40] 3IOU 2.7 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C99 [40] 3IOV 3.5 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C99-Hg [40] 3IOW 3 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C90 [40] 3IO4 3 Å 
Huntingtin amino-terminal region with 17 Gln residues- 
crystal C90 [40] 3IO6 3.7 Å 
Anti-huntingtin VL domain in complex with huntingtin 
peptide (EKLMKAFESLKSFQ) 3LRH 2.6 Å 
Htt36Q3H-EX1-X1-C1 (Alpha) [41] 4FE8 2.8 Å 
Htt36Q3H-EX1-X1-C2 (Beta) [41] 4FEB 2.8 Å 
Htt36Q3H [41] 4FEC 2.8 Å 
Htt36Q3H [41] 4FED 2.8 Å 
Table 1-1. Molecular structures of components of huntingtin exon 1. 
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4.2. Full-Length Huntingtin 
Full-length huntingtin has proven challenging to study, due to the large size of the 
huntingtin protein and extensive post-translational modifications of the protein. Three 
research groups have described production of recombinant full-length huntingtin protein: 
production in insect cells with dimerization and yields of less than 1 mg/L [42]; 
production in insect cells with yields of 1-3 mg/L [43]; and production in mammalian cells 
with significant oligomerization [44]. Huntingtin is predicted to contain 10-36 HEAT 
repeats, which help proteins act as scaffolds for other proteins (MacDonald 2003). 
 
5. Anti-Huntingtin Antibodies 
Dozens of antibodies have been generated that bind to huntingtin. These antibodies 
include several monoclonal anti-polyQ antibodies, including MW1 [45], 3B5H10 [46],1C2 
[47, 48], and 1F8 [49, 50], which is reported to be similar to 1C2 [49]. The X-ray crystal 
structures of 3B5H10 antigen-binding fragment (PDB: 3S96, 4DCQ) [51, 52], 1C2 Fab 
(PDB:4ISV, 4JJ5) [53], and MW1 Fv alone (PDB: 2GSG) and MW1 Fv in complex with a 
GQ10G peptide (PDB: 2OTU, 2OTW) [54] are similar [53]. While each of these antibodies 
has a different apparent affinity for polyQ, 1C2, 3B5H10 and MW1 all have lambda light 
chains, homologous sequences, and strong structural similarity [55]. Several additional 
anti-huntingtin exon 1 antibodies were developed at Caltech by the Patterson Lab [56, 57]. 
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mAb Isotype Epitope Antigen PDB ID (Fragment) 
3B5H10 IgG PolyQ Huntingtin exon 1-
66Q 
4DCQ (Fab) 
3S96 (Fab) 
1C2 IgG PolyQ TATA-binding 
protein-38Q 
4JJ5 (Fab) 
4ISV (Fab) 
MW1 IgG2b PolyQ DRPLA-19Q 2GSG (Fv) 
2OTU (Fv + GQ10G) 
2OTU (Fv + GQ10G) 
MW2 IgM PolyQ DRPLA-35Q and 
TRX-35Q 
 
MW6 IgM PolyQ Soluble huntingtin 
exon 1-67Q 
 
MW7 IgM PolyP Aggregated and 
soluble huntingtin 
exon 1-67Q 
 
MW8 IgG2a AEEPLHRPK Aggregated and 
soluble huntingtin 
exon 1-67Q 
 
Table 1-2. Monoclonal anti-huntingtin exon 1 antibodies. 
 
Figure 1-1. Schematic of anti-huntingtin exon 1 epitope specificity. 
 
6. Linear Lattice Model for PolyQ 
The “linear lattice” hypothesis for the polyQ repeat of huntingtin proposes that polyQ 
retains a random-coil structure for both normal and expanded polyQ in the soluble, 
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monomeric form. However, the increase in number of binding epitopes in expanded polyQ 
compared with normal polyQ results in avidity effects that cause higher apparent affinities 
for bivalent proteins such as antibodies [58]. This could induce altered binding interactions 
with other proteins or other huntingtin polyQ repeats, leading to the neuronal toxicity seen 
in HD. 
Previous results from the Bjorkman lab have indicated that the polyQ repeats in 
huntingtin exon 1 are unstructured, even in huntingtin with expanded polyQ repeats.  
The affinity of the anti-polyQ antibody MW1 to huntingtin exon 1 protein was shown to 
increase in a polyQ-length dependent manner, and binding of multiple antigen-binding 
fragments (Fabs) of MW1 to expanded polyQ tracts was observed. In addition, circular 
dichroism studies demonstrated that huntingtin exon 1-TRX fusion proteins with 16–46 
glutamines exhibited a random coil conformation in solution, and no evidence was found 
for a global conformation change above 37 glutamines [54, 58]. Surface plasmon 
resonance (SPR) and analytical ultracentrifugation (AUC) studies also demonstrated that 
multiple MW1 Fabs bound to expanded polyQ tracts [58]. 
From these binding and structural data, we formulated a linear lattice model to explain 
the apparent targeting of expanded polyQ tracts by anti-polyQ antibodies [58]. This 
model is based on models for binding of DNA to DNA binding proteins [59], which 
suggest that multivalent polyQ binding proteins, such as antibodies, will be able to 
discriminate between normal and expanded polyQ. This model for polyQ repeats of 
huntingtin plays a central role in each project described in this thesis. 
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1. HIGHLIGHTS 
• We assessed binding of MW1 and 3B5H10 anti-polyQ monoclonal antibodies and 
Fabs to normal and expanded huntingtin exon 1 polyQ repeats. 
• Western and dot blots revealed binding of MW1 and 3B5H10 IgGs to both short and 
expanded polyQ tracts in huntingtin exon 1 fusion proteins. 
• Equilibrium gel filtration studies showed that multiple MW1 or 3B5H10 Fabs bound to 
a huntingtin exon 1 fusion protein with 39 glutamines. 
• Selectivity of antibodies for specific conformations of polyQ to distinguish species of 
huntingtin exon 1 fusion protein was not observed, and no evidence for a 
conformational transition between soluble wild type and mutant huntingtin exon 1 
was found. 
 
2. ABSTRACT 
Huntington’s disease (HD) is caused by expansion of a polyglutamine (polyQ) repeat in 
the huntingtin protein. A structural basis for the apparent transition between normal and 
disease-causing expanded polyQ repeats of huntingtin is unknown. The ‘linear lattice’ 
model proposed random-coil structures for both normal and expanded polyQ in the 
preaggregation state. Consistent with this model, the affinity and stoichiometry of the 
anti-polyQ antibody MW1 increased with the number of glutamines. An opposing 
‘structural toxic threshold’ model proposed a conformational change above the 
pathogenic polyQ threshold resulting in a specific toxic conformation for expanded 
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polyQ. Support for this model was provided by the anti-polyQ antibody 3B5H10, which 
was reported to specifically recognize a distinct pathologic conformation of soluble 
expanded polyQ. To distinguish between these models, we directly compared binding of 
MW1 and 3B5H10 to normal and expanded polyQ repeats within huntingtin exon 1 
fusion proteins. We found similar binding characteristics for both antibodies. First, both 
antibodies bound to normal, as well as expanded, polyQ in huntingtin exon 1 fusion 
proteins. Second, an expanded polyQ tract contained multiple epitopes for antigen-
binding fragments (Fabs) of both antibodies, demonstrating that 3B5H10 does not 
recognize a single epitope specific to expanded polyQ. Finally, small angle X-ray 
scattering and dynamic light scattering revealed similar binding modes for MW1 and 
3B5H10 Fab-huntingtin exon 1 complexes. Together, these results support the linear 
lattice model for polyQ binding proteins, suggesting that the hypothesized pathologic 
conformation of soluble expanded polyQ is not a valid target for drug design. 
 
3. INTRODUCTION 
Huntington’s disease (HD) is a fatal neurodegenerative disorder characterized clinically 
by psychiatric symptoms, cognitive decline, and uncontrolled movements [36]. HD is 
caused by expansion of a CAG repeat within exon 1 of HTT (previously HD) that 
encodes an expanded polyglutamine (polyQ) tract in the N-terminal portion of the 
huntingtin protein. A pathologic threshold exists for HD, in which HD is fully penetrant in 
patients with 42 or more glutamines in the huntingtin protein, but no disease is found in 
individuals with 36 or fewer glutamines, while huntingtin with 37 to 41 glutamines 
exhibits reduced HD penetrance [60]. Although a structural basis for an apparent 
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normal-disease threshold is unknown, several hypotheses exist for the conformation of 
monomeric, soluble polyQ in normal and expanded huntingtin protein. 
The ‘linear lattice’ hypothesis proposed that polyQ retains a random-coil structure for 
both normal and expanded polyQ in the preaggregation state. In this model, the increase 
in number of binding epitopes in expanded polyQ compared with normal polyQ results in 
avidity effects that cause higher apparent affinities for bivalent proteins such as 
antibodies [58]. This could induce altered binding interactions with other cellular proteins 
or other polyQ repeats, leading to neuronal toxicity. Consistent with this model, the 
affinity of the anti-polyQ antibody MW1 to huntingtin amino terminal protein encoded by 
exon 1 (hereafter called huntingtin exon 1 protein) increased in a polyQ-length 
dependent manner, and binding of multiple antigen-binding fragments (Fabs) of MW1 to 
expanded polyQ tracts was observed. In addition, huntingtin exon 1 protein with 16 – 46 
glutamines exhibited a random coil conformation in solution, and no evidence was found 
for a global conformation change above 37 glutamines [54, 58]. Surface plasmon 
resonance (SPR) and analytical ultracentrifugation (AUC) studies also demonstrated that 
multiple MW1 Fabs bound to expanded polyQ tracts [58]. The X-ray crystal structure of a 
GQ10G peptide bound to the variable regions of MW1 revealed that a short polyQ tract 
adopted an extended structure in a diagonal binding groove across the antigen-binding 
site of MW1 [54]. Additional binding studies using the anti-polyQ antibody 1C2 [48] 
showed that 1C2 also exhibited preferential binding to expanded polyQ due to avidity 
effects, and this preferential binding was not due to a mutant huntingtin-specific toxic 
structure recognized by 1C2 [53]. 
In contrast, the ‘structural toxic threshold’ model proposed that a conformational 
transition occurs in polyQ repeats that are longer than the pathological threshold, which 
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results in a specific toxic conformation for monomeric expanded polyQ that could 
potentially be recognized by antibodies [61]. According to this model, the postulated 
pathologic conformation could be directly toxic or it could alter interactions between 
mutant huntingtin and its binding partners; in either case, the pathologic conformation 
could be targeted for drug design. Support for this model was provided by studies of the 
anti-polyQ antibody 3B5H10, which was reported to recognize a single epitope 
representing a distinct pathologic conformation of soluble expanded polyQ [52, 62]. In 
these studies, 3B5H10 IgG preferentially bound to expanded polyQ, and a two-stranded 
β-hairpin conformation of polyQ was modeled into the predicted polyQ-binding groove of 
the 3B5H10 Fab structure [52]. Support for this model was provided by a gel filtration 
assay of 3B5H10 Fab binding to a Q39-containing huntingtin exon 1 fusion (HD-39Q) 
protein, which was interpreted to demonstrate a binding stoichiometry of 1:1 3B5H10 
Fab:HD-39Q [62]. These results were suggested to indicate that 3B5H10 binds to a 
single structured polyQ epitope only present in expanded polyQ, as per the structural 
toxic threshold hypothesis. Modeling of small-angle X-ray scattering (SAXS) data was 
interpreted as showing that 3B5H10 Fab bound to HD-39Q in a 2:2 3B5H10 Fab:HD-
39Q complex in which each 3B5H10 Fab recognized one subunit of an HD-39Q dimer 
through binding to a two-stranded β-hairpin conformation of polyQ [52]. Contradictory 
evidence was provided by a recent report demonstrating that pull-down assays and 
surface plasmon resonance (SPR) studies showed that 3B5H10 IgG, like MW1 and 1C2 
IgGs, could bind to short polyQ tracts, as expected given the high sequence and 
structural similarities between the three antibodies [53]. 
Here we compared the recognition properties of the anti-polyQ monoclonal antibodies 
MW1 and 3B5H10 by studying their interactions with a polyQ-containing fragment of 
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huntingtin. Using expressed and purified huntingtin exon 1-thioredoxin (TRX) fusion 
proteins containing 16 to 46 glutamines (HD-16Q, HD-25Q, HD-39Q, HD-46Q) (Fig. 1a), 
we directly compared the interactions between soluble huntingtin and these anti-polyQ 
antibodies using biochemical and biophysical analysis techniques. We found that both 
MW1 and 3B5H10 antibodies exhibited similar binding properties, with neither providing 
evidence for a toxic conformation of expanded polyQ. These results argue against 
strategies designed to target a novel toxic conformation of soluble mutant huntingtin 
exon 1 protein in the preaggregation state. 
 
4. RESULTS 
Both MW1 and 3B5H10 antibodies bind to normal and expanded polyQ within 
huntingtin exon 1 proteins 
Western blots were used to evaluate the binding of 3B5H10 and MW1 IgGs to equimolar 
amounts of huntingtin exon 1-TRX fusion proteins and to the TRX tag alone (Fig. 1b). If 
3B5H10 recognizes a toxic conformation present only in expanded polyQ, then unlike 
MW1, it should not bind to short polyQ repeats. In contrast with some previous results 
[52], but consistent with other results [17, 63], we found that both MW1 and 3B5H10 
IgGs bound in a similar manner to huntingtin exon 1 fusion proteins, each capable of 
binding to huntingtin exon 1 proteins containing both normal and expanded polyQ 
repeats. Both IgGs bound to huntingtin exon 1 proteins in a polyQ-dependent manner, 
with a progressively more intense signal with increased polyQ length. Based on these 
results, and previous western blots demonstrating the ability of 3B5H10 to bind to GST-
polyQ with both short and long polyQ repeats [53], we conclude that both antibodies 
   
 
22
recognize a similar polyQ epitope that is present in both normal and expanded huntingtin 
exon 1 proteins. 
In order to determine how it is possible to obtain results appearing to indicate that 
3B5H10 binds only to expanded polyQ, we examined binding of 3B5H10 and MW1 as a 
function of concentration to huntingtin exon 1 proteins with different polyQ repeat 
lengths. Dot blots of serial dilutions of huntingtin exon 1 proteins demonstrated that both 
3B5H10 and MW1 IgGs bound to huntingtin exon 1 proteins in a length- and 
concentration-dependent manner (Fig. 1c). At higher concentrations of huntingtin exon 1 
protein, both IgGs recognized huntingtin exon 1 constructs with polyQ tracts ranging 
from Q16 to Q46. However, at lower concentrations of huntingtin exon 1 protein, a more 
intense signal was observed for the huntingtin exon 1 construct with the longest polyQ 
repeat (HD-46Q) compared to the construct with the shortest polyQ repeat (HD-16Q) 
(Fig. S1b,c). Due to the length- and concentration-dependent binding, conditions can be 
found in which MW1 or 3B5H10 IgG appeared to only bind expanded polyQ, thus 
explaining previously-reported results that 3B5H10 only recognizes huntingtin with 
expanded polyQ [52]. However, for both antibodies, the binding dependence on polyQ 
length was progressive, without a distinct threshold at polyQ lengths >37Q. Thus, avidity 
effects resulted in bivalent IgG versions of 3B5H10 and MW1 showing preferential 
binding to expanded polyQ, as predicted by the linear lattice model for antibody 
interactions with polyQ repeats [55, 58]. 
 
Huntingtin exon 1 proteins are monomeric in solution 
During purification of huntingtin exon 1 fusion proteins, we observed anomalous 
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migration by gel filtration chromatography such that huntingtin exon 1 fusion proteins 
appeared to migrate as higher molecular weight proteins (e.g., dimers) when compared 
with molecular weight standards of globular proteins. To determine the oligomeric state 
of the huntingtin exon 1 fusion proteins, we used a combination of size-exclusion 
chromatography (SEC) with in-line multiangle light scattering (SEC-MALS), a technique 
that can be used to determine the absolute molecular mass of a protein or complex 
independent of shape and model [64]. To evaluate the methodology, we first analyzed 
3B5H10 Fab alone, which migrated as a single monodisperse peak whose derived 
molecular mass closely matched the mass calculated from the amino acid sequence 
(Fig. 2; Table 1). HD-16Q and HD-39Q fusion proteins also migrated as monodisperse 
peaks, and their calculated molecular masses corresponded to monomers in each case 
(Table 1). Thus the anomalous migration of each huntingtin exon 1 protein in positions 
expected for a dimeric version of a globular protein of the same molecular mass results 
from slower migration due to an elongated structure rather than from dimerization. In 
particular, no evidence was found for dimer formation for HD-39Q as predicted in a 
previous study involving the modeling of small-angle X-ray scattering (SAXS) data [52]. 
 
Non-equilibrium gel filtration chromatography analyses yield inconsistent 
apparent binding stoichiometries 
We next replicated published non-equilibrium gel filtration chromatography experiments 
that were conducted to determine the stoichiometry of binding between 3B5H10 Fab and 
huntingtin exon 1 protein with an expanded polyQ repeat using the same proteins: 
3B5H10 Fab and HD-39Q [62]. By varying the ratio of 3B5H10 Fab to HD-39Q, we 
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determined the ratio where the least amount of excess Fab or excess HD-39Q was 
detected, the method previously used to report a 1:1 3B5H10:HD-39Q binding 
stoichiometry [62]. Similar to the published results, we found that unbound 3B5H10 Fab 
was present at ratios greater than 1:1 3B5H10 Fab:HD-39Q, unbound HD-39Q was 
present at ratios less than 1:1, and that the ratio where the least amount excess of Fab or 
excess HD-39Q could be detected was 1:1 (Fig. 3a). As a control, we repeated the non-
equilibrium gel filtration stoichiometry experiment to evaluate the binding behavior of MW1 
Fab and HD-39Q (Fig. 3b), which was previously shown to form a complex with a greater 
than 1:1 stoichiometry [58]. Under non-equilibrium conditions, the stoichiometry of MW1 
Fab:HD-39Q appeared to be less than 1:1. Thus it appeared that non-equilibrium gel 
filtration could not be reliably used to derive an accurate binding stoichiometry for an anti-
polyQ Fab binding to huntingtin exon 1 fusion proteins with expanded polyQ. 
However, we noted that with increasing molar ratios of 3B5H10 Fab:HD-39Q, the complex 
peak eluted earlier on the gel filtration column, suggesting that a complex larger than 1:1 
was forming at the same time as 3B5H10 Fab was dissociating from HD-39Q. Due to the 
anomalous migration of HD-39Q compared with globular proteins using gel filtration 
chromatography (see above), the molecular mass of the 3B5H10 Fab:HD-39Q complex 
peak could not accurately be estimated based on gel filtration migration. Using SEC-
MALS, we found that the complex of 3B5H10 Fab and HD-39Q was polydisperse, and the 
molecular mass of the peak fraction corresponded to a complex composed of greater than 
a 1:1, but less than a 2:1, ratio of 3B5H10 Fab:HD-39Q (Table 1), demonstrating that 
dissociation of the complex occurred during the experiment. In contrast, the complex of 
3B5H10 Fab and HD-16Q migrated as a monodisperse peak, and the calculated 
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molecular mass for a 1:1 3B5H10 Fab:HD-16Q stoichiometric ratio was in close 
agreement with the molecular mass obtained by SEC-MALS (Table 1). 
Taken together, the results for these experiments suggested that binding stoichiometries 
for MW1 and 3B5H10 Fabs binding to huntingtin exon 1 proteins as determined by non-
equilibrium gel filtration are incorrect. This is likely because protein complexes that 
dissociate during this procedure are unable to rebind due to separation by the gel filtration 
column. Therefore depending on the binding kinetics and the amount of separation 
between anti-polyQ Fabs and huntingtin exon 1 proteins on the gel filtration column, the 
binding stoichiometries determined by non-equilibrium gel filtration techniques may be 
artificially low, as has been found in other protein-protein interaction systems evaluated by 
this technique [65, 66]. 
 
Expanded polyQ tracts within huntingtin exon 1 proteins contain multiple epitopes 
for the antigen-binding fragments (Fabs) of MW1 and 3B5H10 
To determine an accurate stoichiometry of binding between HD-39Q and the Fabs of 
3B5H10 and MW1, we used equilibrium gel filtration [67]. In this technique, a 
chromatography column is run with an equilibration buffer containing one of the binding 
partners (e.g., protein A). Different ratios of the binding partners (e.g., protein A and 
protein B) are then injected onto the column. When the amount of additional protein A 
injected is less than that required for formation of a complex, a trough will form at the 
position that protein A migrates. If the amount of additional protein A injected is in 
excess for complex formation, a peak is observed at the position that protein A migrates. 
When the amount of additional protein A injected is at the amount required for complex 
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formation, a flat baseline is observed at the position that protein A migrates. However, 
unless the protein concentration in the equilibration buffer is much greater than the 
affinity of the protein-protein complex, the ratio of protein A to protein B at which a flat 
baseline is observed will not be an integer, in which case the correct stoichiometry can 
be obtained by rounding up to the next integer [65] or by Scatchard analysis [66]. 
Previous measurements demonstrated a higher polyQ binding affinity for 3B5H10 Fab 
than for MW1 Fab: KD = 1.0 µM for 3B5H10 Fab binding to a Q22 or Q41 peptide [53] 
versus KD = 2.2 µM for MW1 Fab binding to HD-39Q [58]. Therefore we used higher 
concentrations of MW1 Fab (1-10 µM) than 3B5H10 Fab (0.5-5 µM) in these 
experiments. 
Complexes containing different ratios of Fab and HD-39Q were incubated together and 
injected onto a gel filtration column equilibrated with the appropriate Fab. A series of 
experiments with different concentrations of 3B5H10 Fab in the equilibration buffer were 
performed. For example, for 5 µM of 3B5H10 Fab in the equilibration buffer, the 
stoichiometry at which no peak or trough was observed was ~2.6:1 (Fig. 4a). Analysis 
with MW1 Fab yielded similar results, with the MW1 Fab:HD-39Q stoichiometry 
approaching 3:1 (Fig. 4b). Therefore for both antibodies, the stoichiometry of binding 
was determined as 3:1 Fab:HD-39Q. 
 
Dynamic light scattering (DLS) revealed similar sizes for complexes of MW1 and 
3B5H10 Fabs with huntingtin exon 1 proteins 
To further investigate complexes of anti-polyQ Fabs bound to huntingtin exon 1 proteins, 
we used dynamic light scattering (DLS) to compare hydrodynamic radii (Rh) of 3B5H10 
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and MW1 Fabs alone, HD-16Q and HD-39Q alone, and complexes of Fab and 
huntingtin exon 1 protein. Fab complexes with HD-16Q were prepared at a 1:1 Fab:HD-
16Q molar ratio, while complexes with HD-39Q were prepared at a 3:1 molar ratio. 
Concentrations of proteins and complexes varied from 1-7 mg/mL, higher than the 
concentrations used for equilibrium gel filtration experiments. As expected, the Rh values 
derived for the 3B5H10 and MW1 Fabs, which are globular proteins of similar 
dimensions, were roughly the same, and both Rh values were smaller than the Rh values 
for HD-16Q and HD-39Q (Table 2), consistent with the proposed elongated structures of 
HD-16Q and HD-39Q [58] (Table 2). Notably, the Rh value for HD-16Q was smaller than 
for HD-39Q, inconsistent with the compact structure proposed for expanded polyQ [52]. 
When complexed with huntingtin exon 1 proteins, both Fabs exhibited qualitatively 
similar behavior: the Rh values were lower for the Fab complexes with HD-16Q than with 
HD-39Q. Based on our gel filtration and SEC-MALS data (Fig. 2,4), the complexes being 
examined by DLS were likely to be 1:1 Fab:HD-16Q complexes and a mixture of 2:1 and 
3:1 Fab:HD-39Q complexes for both Fabs. Consistent with our other results, the 3B5H10 
and MW1 Fabs did not exhibit different properties when binding to huntingtin exon 1 
proteins as would have been expected if 3B5H10, but not MW1, recognized a pathologic 
conformation of expanded polyQ. 
 
Small-angle X-ray scattering revealed similar predicted characteristics for 
complexes of MW1 and 3B5H10 Fabs with huntingtin exon 1 proteins 
We next repeated published small-angle X-ray scattering (SAXS) studies for HD-39Q 
alone and complexed with 3B5H10 Fab [52], comparing results with SAXS data for 
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analogous complexes with MW1 Fab and HD-16Q. We collected SAXS data for samples 
of 3B5H10 and MW1 Fabs alone, HD-16Q, HD-25Q, HD-39Q, and HD-46Q alone, and 
complexes of each Fab with HD-16Q and HD-39Q. With the exception of the HD-46Q 
alone sample, the scattering profiles for the Fabs, huntingtin exon 1 fusion proteins 
alone, and Fab:HD-16Q and Fab:HD-39Q complexes showed ideal sample quality 
characteristics (Fig. S2). Guinier analysis [68] indicated minimal aggregation for both 
Fabs alone and Fabs complexed with HD-16Q and HD-39Q and for all huntingtin exon 1 
fusion proteins alone (Fig. S3). Radii of gyration (Rg) determined by SAXS were 
consistent with Rh values determined by DLS (Table 2). In particular, for measurements 
of huntingtin exon 1 fusion proteins alone, we did not see substantially increased Rh or 
Rg values for HD-39Q compared with HD-16Q, consistent with computational modeling 
of polyQ in aqueous solution suggesting that radii of polyQ tracts of increasing lengths 
are similar [69], but inconsistent with the structural toxic threshold model predicting a 
conformational transition for expanded polyQ tracts [52]. The predicted molecular 
weights of the complexes of 3B5H10 or MW1 Fab bound to HD-16Q in a 1:1 complex 
were similar to the molecular weights calculated based on the extrapolated scattering 
intensity at zero angle [70]. However, 3B5H10 Fab or MW1 Fab bound to HD-39Q 
formed complexes with observed molecular weights larger than a 1:1 complex. Based on 
molecular weight alone, these complexes could be 2:1, 3:1, or 2:2 Fab:HD-39Q 
complexes. A 2:2 3B5H10 Fab:HD-39Q stoichiometry was postulated to account for 
previous SAXS data [52]. However, our SEC-MALS and equilibrium gel filtration data 
demonstrated that 3B5H10 Fab does not bind to HD-39Q in a 2:2 ratio (Fig. 2). 
Therefore, we interpret our SAXS data for both 3B5H10 and MW1 Fab binding to HD-
39Q as evidence for mixtures of 2:1 and 3:1 Fab:HD-39Q complexes. 
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Kratky analysis was used to evaluate the relative degree of folding of each sample [71]. 
The Kratky plots for MW1 and 3B5H10 Fabs alone yielded bell-shaped peaks consistent 
with globular proteins [72, 73] (Fig. 5a). By contrast, the Kratky plots for HD-16Q and 
HD-39Q were broader, with less degrease at higher scattering angles, consistent with 
flexible or unfolded proteins [72, 73] (Fig. 5b). Thus we found no evidence for a 
conformational change occurring for HD-39Q relative to HD-16Q. Similarly, we found no 
systematic differences for 3B5H10 versus MW1 Fab complexes with either HD-16Q or 
HD-39Q (Fig. 5c,d). These results are consistent with both Fabs exhibiting similar 
recognition properties for polyQ tracts. 
Three-dimensional structures can be modeled into SAXS profiles; however, modeling is 
limited by the one-dimensional nature of SAXS data, and more than one 3-D shape can 
produce the same one-dimensional scattering profile [74]. We did not attempt to fit 
atomistic models into the SAXS data as done in a previous study [52] because (i) the 
complete 3-D structure of huntingtin exon 1 protein is unknown, (ii) the polyQ tract within 
huntingtin exon 1 fusion proteins adopts flexible random coil structures in solution [58], 
and (iii) the arrangements between polyQ tracts, the remainder of huntingtin exon 1, the 
TRX fusion partner, and the His purification tag cannot be predicted. Nor did we assume 
that the huntingtin exon 1 fusion proteins were dimeric, as also done for interpretation of 
SAXS data involving HD-39Q bound to 3B5H10 Fab [52], because our SEC-MALS data 
demonstrated that HD-39Q is monomeric in solution (Fig. 2). Instead, we used minimal 
assumptions to generate ab initio models that predicted molecular envelopes from the 
SAXS data for each of the well-behaved samples. We did not find notable differences 
between 3B5H10:HD-39Q and MW1:HD-39Q complexes based on Rg, Dmax, or shape or 
volume of calculated envelopes (Fig. 6, Table 2), as would be predicted by the toxic 
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conformation model suggesting that 3B5H10, but not MW1, recognizes a compact 
conformation of expanded polyQ [52]. Instead, in agreement with experiments described 
above and in previous reports [53-55, 58], the SAXS results were consistent with 
recognition of multiple epitopes within a linear lattice of expanded polyQ by both Fabs. 
 
5. DISCUSSION 
The structure of huntingtin exon 1 protein in the preaggregation state, particularly the 
conformation of the expanded polyQ repeat, is hypothesized to be critical in 
understanding the pathogenesis of HD. However, the structure of the basic components 
of huntingtin exon 1 remains controversial. An X-ray crystal structure of a Q17 huntingtin 
N-terminal region fused to MBP showed that a short polyQ region could adopt either α-
helical, loop, or random coil conformations [40]. The structure of a Q10 peptide bound to 
the anti-polyQ antibody MW1 revealed an extended structure [54]. Other recent work 
suggested that the polyQ repeat acts as a flexible hinge that exhibits reduced flexibility 
at extended polyQ lengths [75]. In the present study, we show that the binding properties 
of the anti-polyQ antibodies MW1 and 3B5H10 support the ‘linear lattice’ model for the 
structure of soluble polyQ in the context of a huntingtin exon 1 fusion protein. This model 
postulates that both normal and expanded polyQ tracts in the preaggregation state are 
random-coil structures, with expanded polyQ repeats containing more epitopes 
recognized by antibodies or other binding proteins than normal polyQ tracts [58]. Several 
lines of evidence, reported here and in previous publications [17, 53], have shown that 
3B5H10 and MW1 IgGs can bind to a normal polyQ repeat, demonstrating that neither 
antibody preferentially recognizes a novel structure formed by expanded polyQ, but 
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instead both recognize a short stretch of polyQ. This conclusion is in contrast to other 
studies suggesting that 3B5H10 bound preferentially to expanded polyQ repeats of 
mutant huntingtin according to a ‘structural toxic threshold’ model, in which a 
conformational transition occurs in the polyQ repeat of huntingtin exon 1 protein at the 
pathologic threshold (>37Q) [52]. Instead our results agree with the conclusions of a 
recent study comparing the binding of anti-polyQ antibodies 1C2 and 3B5H10 to polyQ 
repeats [53].  
To evaluate whether an expanded polyQ tract contains one epitope for anti-polyQ Fabs 
as predicted by the structural toxic threshold model, or multiple epitopes for the Fabs as 
predicted by the linear lattice model, we evaluated complexes using equilibrium gel 
filtration chromatography. Our results demonstrated that the stoichiometry of both 
3B5H10 Fab:HD-39Q and MW1 Fab:HD-39Q complexes was ~3:1 Fab:HD-39Q for both 
Fabs, thus neither Fab preferentially recognizes a novel structure formed by expanded 
polyQ. Consistent with this result, we confirmed that both 3B5H10 and MW1 IgGs 
recognized unexpanded polyQ, in direct contradiction to the structural toxic threshold 
model. We also used SAXS and DLS to further study the conformation of normal and 
expanded forms of huntingtin exon 1 protein, alone and in complex with MW1 or 3B5H10 
Fab. This allowed us to determine the globularity of the protein complexes and their 
approximate oligomeric states, which revealed striking similarities between MW1 and 
3B5H10 Fabs, both when unliganded and when bound to HD-16Q or HD-39Q. Thus a 
combination of equilibrium gel filtration chromatography, DLS, and SAXS data are 
consistent with a linear lattice mode of recognition of unstructured polyQ for both 
3B5H10 and MW1 antibodies. Sharing the same general ligand-binding properties is 
consistent with the high degree of sequence and structural similarity relating 3B5H10 
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and MW1 [53]: the variable regions are related by 53% (VH domain) and 99% (VL 
domain) sequence identity and a root mean square deviation of 0.59 Å for superposition 
of VH-VL regions of the 3B5H10 (PDB code 3S96) and MW1 (PDB code 2GSG) crystal 
structures (calculated for all Cα atoms). In addition, the antigen-binding sites of both 
antibodies include an unusual diagonal groove [53] shown to accommodate a single 
extended stretch of polyQ in an MW1-polyQ co-crystal structure [54], and thus unlikely to 
bind to a two-stranded β-hairpin structure of polyQ, as modeled for the HD-39Q 
interaction with 3B5H10 Fab [52]. 
Reduced penetrance is seen in patients with between 37 and 41 glutamine repeats in 
the huntingtin protein, which may be best explained by a quantitative change in a rate-
limiting process in which the effects can be countered in some patients and not in others 
due to environmental or genetic modifiers. This reduced penetrance is consistent with a 
continuous linear lattice effect that is weak at lower polyQ repeat lengths and 
progressively stronger at larger repeat lengths. These results are relevant to potential 
therapeutic approaches to target soluble expanded polyQ in a lag period preceding 
aggregation. As we find no evidence for recognition of a specific conformation of 
expanded polyQ within huntingtin exon 1 proteins in either this study or previous studies 
[53-55, 58], we suggest that efforts to target expanded polyQ using monomeric binding 
partners are unlikely to be successful in discriminating polyQ stretches found in non-
disease proteins such as transcription factors [76, 77] from expanded polyQ within 
mutant huntingtin exon 1. Instead, we suggest strategies in which reagents that 
recognize short stretches of polyQ are covalently linked to allow avidity effects to 
discriminate between short and expanded polyQ tracts. 
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6. MATERIALS AND METHODS 
Protein expression and purification 
Human huntingtin exon 1 encoded protein (comprising 91 amino acids when containing 
16 glutamine residues) including different sized polyQ segments (Q16, Q25, Q39, and 
Q46) coded for by CAG or CAA/CAG repeats was expressed as a fusion protein with 
thioredoxin (TRX). Exon 1 fusion proteins were purified as previously described [58] with 
the following modifications: autoinduction was used to culture cells to high densities [78], 
and sonication was used for cell lysis. Purified proteins were flash frozen and stored at -
80°C in 50 mM Tris (pH 8.0) and 150 mM NaCl. 
MW1 IgG2b was purified from ascites fluid by protein A affinity chromatography (GE 
Healthcare). MW1 Fab was prepared by papain cleavage of MW1 IgG using a ratio of 
1:25 (papain:MW1 by weight) for 30 minutes at 37°C. Fabs were separated from the Fc 
fragment using protein A affinity chromatography (GE Healthcare) and then further 
purified by gel filtration chromatography (Superdex 200 10/300 GL). 
3B5H10 Fab was expressed and purified as previously described for other IgGs [79]. 
Briefly, the 3B5H10 light chain (LC) gene and a C-terminally 6x-His tagged heavy chain 
(HC) gene were subcloned separately into the pTT5 mammalian expression vector 
(NRC Biotechnology Research Institute), and 3B5H10 Fab was expressed by transient 
co-transfection of HEK293-6E (NRC Biotechnology Research Institute) cells and purified 
from supernatants using Ni2+-NTA affinity chromatography and gel filtration 
chromatography (Superdex 200 10/300 or 16/60). 
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Protein concentrations were determined using 280 nm extinction coefficients of 80,830 
M-1 cm-1 (3B5H10 Fab), 78,310 M-1 cm-1 (MW1 Fab), 14,180 M-1 cm-1 (TRX), 14,180 M-1 
cm-1 (HD-16Q), and 14,180 M-1 cm-1 (HD-39Q). Extinction coefficients were calculated 
based on amino acid sequence using ProtParam 
(http://web.expasy.org/protparam/protpar-ref.html).  
 
Western and dot blot analyses 
Equimolar amounts of purified huntingtin exon 1 protein and TRX were loaded and 
separated on an Any kD Mini-PROTEAN gel (Bio-Rad Laboratories, Hercules, CA) at 
175 V for 40 minutes, followed by transfer to a nitrocellulose membrane at 100 V for 1 
hour. After blocking for 1 hour in TBST with 3% BSA, membranes were incubated 
overnight at 4°C with 3B5H10 IgG (Sigma, St. Louis, MO), MW1 IgG (purified from 
ascites), or rabbit polyclonal N17 huntingtin IgG [80] at 1:75,000 or, 1:10,000, or 1:7,500 
respectively. Membranes were washed with TBST and incubated with HRP-conjugated 
anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA) or HRP-
conjugated anti-rabbit IgG (Jackson Immunoresearch Laboratories) for 1 hour at room 
temperature. Membranes were washed again, and antibody binding was detected using 
Amersham Enhanced Chemiluminescence (ECL) Prime Western Blotting Detection 
Reagent (GE Life Sciences, Uppsala, Sweden). Western blots were imaged using a 
ChemiDoc MP Imaging System (Bio-Rad Laboratories). Equimolar amounts of purified 
huntingtin exon 1 protein and TRX were also analyzed by SDS-PAGE on an Any kD 
Mini-PROTEAN gel (Bio-Rad Laboratories) and stained with Coomassie. 
Equimolar amounts of huntingtin exon 1 fusion protein and TRX were serially diluted in 
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50 mM Tris (pH 8.0), 150 mM NaCl and spotted onto nitrocellulose membranes. 
Membranes were washed with TBST and probed with 3B5H10, MW1, or mouse 
monoclonal anti-TRX (Genscript, Piscataway, NJ) IgGs overnight at 4°C. HRP-
conjugated goat anti-mouse secondary antibody (Jackson Immunoresearch 
Laboratories) was used to quantitate antibody binding to proteins on the membrane, and 
antibody binding was detected using Amersham ECL Prime Western Blotting Detection 
Reagent (GE Life Sciences). Densitometry of blots was performed using Image Lab 
5.2.1 Software (Bio-Rad Laboratories). Densities were expressed as a ratio relative to 
the density observed for HD-16Q (western blots) or 20 pmol HD-16Q (dot blots). 
 
SEC-MALS 
Purified proteins or protein complexes were characterized by SEC-MALS to determine 
absolute molecular masses [64]. Proteins were concentrated to 1 mg/mL, passed 
through a 0.2 µm filter (Millipore), and injected onto a Superdex 200 10/300 GL gel-
filtration chromatography column equilibrated in a buffer containing 20 mM Tris (pH 8.0) 
and 100 mM NaCl. The chromatography system was connected with an 18-angle light-
scattering detector (DAWN HELEOS II; Wyatt Technology), a dynamic light-scattering 
detector (DynaPro Nanostar; Wyatt Technology), and a refractive index detector (Optilab 
t-rEX; Wyatt Technology). Data were collected every second at a flow rate of 0.5 mL/min 
at 25°C. Data analysis was carried out using the program ASTRA 6, yielding the molar 
mass and distribution of mass (polydispersity) of the sample. 
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Non-equilibrium gel filtration chromatography 
Non-equilibrium protein interaction experiments were carried out on a Superdex 200 PC 
3.2/30 gel-filtration column (GE Healthcare) equilibrated in a buffer containing 50 mM 
Tris (pH 8.0) and 150 mM NaCl. A final concentration of 7 µM HD-39Q was used for all 
experiments, with 3B5H10 and MW1 Fab concentrations varied to create Fab:HD-39Q 
complexes with final molar ratios of 0.25:1, 0.5:1, 1:1, 1.5:1, 2:1, and 3:1. 50 µL of each 
complex was injected and flowed through the column at 50 µL/min at room temperature. 
The absorbance of the eluent was monitored at 280 nm. 
 
Equilibrium gel filtration chromatography 
A Superdex 200 PC 3.2/30 (GE Healthcare) gel filtration column was equilibrated and 
run with equilibration buffer: 50 mM Tris (pH 8.0), 150 mM NaCl and a specific 
concentration of 3B5H10 Fab (0.5 µM, 0.75 µM, 1 µM, or 5 µM) or MW1 Fab (1 µM, 3 
µM, 5 µM, or 10 µM). Complexes containing 0:1, 1:1, 2:1, or 3:1 molar ratios of a 
variable concentration of Fab:HD-39Q, where the concentration of HD-39Q was equal to 
the concentration of Fab in the equilibration buffer, were incubated for 30 minutes at 
room temperature in equilibration buffer and then injected onto the column. 
Chromatography was performed at a flow rate of 50 µL/min using a SMART 
micropurification system (Pharmacia), and the absorbance of the eluent was monitored 
at 280 nm. 
 
Dynamic light scattering (DLS) 
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DLS measurements were conducted on a DynaPro® NanoStarTM (Wyatt Technology, 
Goleta, CA) at 25°C. All samples were purified using a Superdex 200 10/300 column in 
50 mM Tris (pH 8.0), 150 mM NaCl prior to DLS and SAXS measurements, and the 
same sample preparations were used for both experiments. Fractions were pooled and 
concentrated to at least 2 mg/mL and filtered through 0.2 µm membranes (Millipore). 
Samples were equilibrated to 25°C prior to DLS measurements. Data were analyzed 
using Dynamics V7.1.2 software (Wyatt Technology) to calculate hydrodynamic radii 
(Rh). 
 
Small angle X-ray scattering (SAXS) 
Small angle X-ray scattering experiments were conducted at beamline 4-2 at SSRL 
using a Rayonix MX225-HE detector at a distance of 2500 mm, using 1.13 Å wavelength 
X-rays. Protein preparations for DLS measurements were used for SAXS data collection. 
For each protein or complex, scattering intensity was measured at four protein 
concentrations (0.5-7 mg/mL), collecting 10 exposures of 1 second each, covering a 
momentum transfer (q) range of 0.0047-0.375 1/Å. The scattering profile for the buffer 
was obtained in the same manner. Scattering curves collected from protein samples 
were corrected for background scattering using the intensity data collected from the 
buffer alone using SasTool [81]. 
SAXS scattering curves were scaled, high and low q regions of scattering curves were 
merged to extrapolate to infinite dilution, and Guinier analysis was performed using 
PRIMUS [82]. Rg values were calculated from Guinier plots. Scattering curves were 
overlaid to check for concentration-dependent effects on the scattering profile. GNOM 
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[68] was used to calculate pairwise distribution functions. Porod volumes were 
calculated from DATPOROD [83]. Molecular weight was calculated by using the formula 
MMp = I(0)p/cp*(MMst)/(I(0)st/cst), where MMp and MMst are molecular masses of the 
protein and lysozyme standard, respectively, I(0)p and I(0)st are the scattering angles at 
zero intensity, and cp and cst are the concentrations [70]. The protein concentration, cp, 
was calculated using the equation A = ε L cp, where A is absorbance at 280 nm, ε is the 
molar extinction coefficient, and L is the path length. The extinction coefficient and 
theoretical molecular weight for a 3:1 and a 1:1 Fab:huntingtin exon 1 protein complex 
are different. Because we most likely observed a mixture of 1:1, 2:1, and 3:1 
Fab:huntingtin complexes, we listed a lower limit (100% 1:1) and upper limit (100% 3:1) 
for potential complex sizes. 
For each protein or complex, at least 10 ab initio models were generated using DAMMIF 
[84]. Models were superimposed and averaged using DAMMIN [85] and DAMAVER [86] 
in the ATSAS package [83], and resulting models were filled with dummy atoms. 
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7. FIGURE LEGENDS 
Fig. 1. Biochemical analyses of huntingtin exon 1:3B5H10 IgG and huntingtin exon 
1:MW1 IgG complexes. (a) Schematic of organization of human huntingtin exon 1- 
thioredoxin (TRX) fusion proteins used in this study. The bar above the domain structure 
represents the huntingtin exon 1 fragment with the polyQ tract indicated by a bracket. 
N17, N-terminal 17 amino acid domain. PRR, proline rich region. (b) Western blot 
analysis of 3B5H10 and MW1 IgG binding to huntingtin exon 1 fusion proteins with 
variable numbers of glutamines. Both MW1 and 3B5H10 IgGs bound to huntingtin exon 
1 proteins with normal and expanded polyQ repeats, but did not bind the TRX-tag control 
(top panels). Equimolar loading of huntingtin exon 1 fusion proteins was verified by 
blotting with the N17 antibody that recognizes the first 17 residues of huntingtin [80] 
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(bottom panel). Densitometry of bands in blots is shown in Fig. S1b. (c) Dot blot analysis 
of 3B5H10 and MW1 IgG binding to huntingtin exon 1 fusion proteins (top panels). 
Equimolar loading of huntingtin proteins was verified by blotting with anti-TRX (bottom 
panel). Densitometry results are shown in Fig. S1c. As huntingtin concentrations 
decreased, binding to short polyQ repeats of huntingtin exon 1 protein was reduced 
more than binding to long polyQ repeats for both anti-polyQ antibodies MW1 and 
3B5H10. 
 
Fig. 2. SEC-MALS profiles of huntingtin exon 1 protein and Fab:huntingtin exon 1 
complexes. Complexes were prepared with ~3-fold molar excess of Fab for experiments 
with HD-39Q and ~equal molar ratios for experiments with HD-16Q and then injected 
onto a Superdex 200 10/300 GL gel filtration column. The differential refractive index 
(left axis) is plotted against elution time from a gel filtration column and overlaid with the 
molar mass determined for each peak (right axis). 
 
Fig. 3. Non-equilibrium gel filtration chromatography analyses of Fab:HD-39Q 
complexes. Fabs of MW1 or 3B5H10 and HD-39Q were incubated at Fab:HD-39Q molar 
ratios of 0.25:1, 0.5:1, 1:1, 1.5:1, 2:1, and 3:1, and passed over a gel filtration column 
run under non-equilibrium conditions. An HD-39Q concentration of 7 µM was used for all 
experiments. (a) 3B5H10 Fab in complex with HD-39Q. (b) MW1 Fab in complex with 
HD-39Q. 
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Fig. 4. Equilibrium gel filtration chromatography analyses of Fab:HD-39Q complexes. 
MW1 or 3B5H10 Fabs and HD-39Q were incubated at the indicated molar ratios and 
passed over a gel filtration column run in an equilibration buffer containing the indicated 
concentrations of 3B5H10 or MW1 Fab. For each experiment, HD-39Q at the same 
concentration as the Fab in the equilibration buffer was incubated with Fab at Fab:HD-
39Q molar ratios of 0:1, 1:1, 2:1, and 3:1 in the equilibration buffer and injected onto a 
column that had been equilibrated in the equilibration buffer. The peak eluting first 
corresponds to a Fab:HD-39Q complex. The second peak or trough occurs at the 
volume where free Fab elutes. (a) 3B5H10 Fab in complex with HD-39Q using 0.5 µM, 
0.75 µM, 1.0 µM, and 5 µM 3B5H10 Fab in the equilibration buffer. (b) MW1 Fab in 
complex with HD-39Q using 1 µM, 3 µM, 5 µM, and 10 µM MW1 Fab in the equilibration 
buffer. The stoichiometry approached 3:1 Fab:HD-39Q for both Fabs. 
 
Fig. 5. Kratky plot analyses of SAXS data for huntingtin exon 1 fusion proteins, MW1 and 
3B5H10 Fabs, and complexes of Fabs and huntingtin exon 1 proteins. Each plot shows 
the intensity of scattering plotted as Iq2 versus q, where q is scattering angle (Å-1) and I 
is the scattering intensity. (a) For MW1 and 3B5H10 Fabs, each plot exhibited one 
maximum, indicating that these are globular proteins. (b) HD-16Q and HD-39Q showed 
a plateau at higher q values, suggesting that these proteins include disordered regions, 
with decreasing globular character as the polyQ repeat length increased. (c) Curves for 
3B5H10:HD-16Q and MW1:HD-16Q complexes were similar, each exhibiting broad 
single peaks. (d) Curves for 3B5H10:HD-39Q and MW1:HD-39Q complexes were 
similar, each exhibiting a similar low plateau. 
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Fig. 6. Ab initio models derived from SAXS data for huntingtin exon 1 fusion proteins, 
MW1 and 3B5H10 Fabs, and Fabs:huntingtin exon 1 complexes. Calculated molecular 
envelopes filled with dummy atoms reveal the shapes of (a) 3B5H10 Fab, MW1 Fab, 
HD-16Q, HD-39Q, (b) 3B5H10 Fab:HD-16Q, MW1 Fab:HD-16Q, 3B5H10 Fab:HD-39Q, 
MW1 Fab:HD-39Q. 
 
Fig. S1. Biochemical analyses of huntingtin exon 1:3B5H10 IgG and huntingtin exon 
1:MW1 IgG complexes. (a) SDS-PAGE analysis of purified huntingtin exon 1 fusion 
proteins and thioredoxin under reducing conditions. (b) Densitometry analysis of western 
blots in Fig. 1b. (c) Densitometry analysis of dot blots in Fig. 1c. 
 
Fig. S2. SAXS scattering profiles. Log(I) vs. q scattering profiles were superimposable 
when scaled for concentration, indicating high sample quality. HD-46Q showed variation 
at different concentrations, suggesting aggregation or other non-ideal behavior. The 
three lines indicate a serial dilution series of protein. Green is the scattering profile from 
the highest and light blue is the scattering profile of the lowest protein concentration. 
 
Fig. S3. Guinier plots (left) and pair distribution functions (right). Guinier plots showed 
linear behavior in low q ranges, except for HD-46Q, which showed non-linear behavior 
indicative of aggregation. Pair distribution functions, P(r), were obtained from scattering 
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curves using AUTOGNOM [87], and fell smoothly to zero at Dmax, the maximum linear 
dimension of scattered particles.  
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TABLES 
Molecule or complex SEC-MALS Molecular Mass (kDa) 
 Observed Calculated 
HD-16Q 23.1 24.3 
HD-39Q 24.3 27.2 
3B5H10 Fab 44.7 48.1 
HD-16Q + 3B5H10 Fab 63.0 72.4 (1:1) 
HD-39Q + 3B5H10 Fab 110.3 75.3 (1:1) 
123.5 (2:1) 
171.5 (3:1) 
 
Table 1. SEC-MALS analysis of huntingtin exon 1 proteins and 3B5H10 Fab:huntingtin 
exon 1 complexes. The observed and calculated molecular masses of the proteins are 
listed. 
 
Molecule or 
complex 
MW (kDa), 
calculated 
MW (kDa), 
observed 
R
h
 
(Å) 
R
g
 
(Å) 
D
max
 
(Å) 
Porod 
volume (105) 
(Å3) 
3B5H10 Fab 48,118 54,900 33 28 98 0.6 
MW1 Fab 47,330 49,300 33 26 87 0.6 
HD-16Q 24,279 40,000 40 49 168 0.8 
HD-39Q 27,226 21,700 47 52 164 0.9 
3B5H10 
Fab:HD-16Q 
72,379 62,600 37 35 128 0.8 
MW1 Fab:HD-
16Q 
71,609 71,200 41 40 141 0.9 
3B5H10 
Fab:HD-39Q 
75,344 (1:1) 
171,579 (3:1) 
137,000 - 
178,000 
59 54 194 3 
MW1 Fab:HD-
39Q 
74,556 (1:1) 
169,216 (3:1) 
125,000 - 
162,000 
52 50 173 2 
 
   
 
55
Table 2. Structural parameters of huntingtin exon 1 proteins, MW1 and 3B5H10 Fabs, 
and Fab:huntingtin exon 1 protein complexes from SAXS and DLS. MW observed, Rg, 
Dmax, and Porod volume were obtained from SAXS. Rh was obtained from DLS. The 
extinction coefficient and theoretical molecular weight for a 3:1 and a 1:1 Fab:huntingtin 
exon 1 protein complex are different; therefore two molecular weights are listed as 
observed for Fab:HD-39Q complexes. DLS and SAXS experiments were performed on 
the same samples. MW, molecular weight. Rh, hydrodynamic radius. Rg, radius of 
gyration. Dmax, the maximum linear dimension of scattered particles. 
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Chapter 3: Biophysical Characterization of Huntingtin 
1. Huntingtin Expression and Purification 
Because huntingtin rapidly aggregates in solution (Chen et al., 2002; Colby et al., 2006), 
huntingtin exon 1 was expressed as a fusion protein with E. coli thioredoxin (TRX) to 
increase the expression of soluble huntingtin [88] in a pET-32a vector (Novagen) with a 
single N-terminal His6 tag. Constructs contained the TRX gene, a linker segment 
(GSGSGERQHMDSPDLGTDDDDK), the HD exon 1 insert, and a His6 tag. Proteins 
were overexpressed in BL21(DE3) cells (Novagen) by one of two methods: IPTG 
induction or autoinduction. Proteins were released by osmotic shock by using a 
modification of a published method [88], or by sonication. For osmotic shock, the cells 
were spun at 6,000 x g for 10 min at 4°C, and pellets were resuspended in 15 mM Tris-
HCl, pH 8.0, and incubated 45 min with shaking at 4°C. Osmotically shocked cells were 
spun at 15,000 x g for 10 min at 4°C, and the supernatant containing the protein of 
interest was incubated with Ni nitriloacetate beads (Qiagen). Proteins were eluted in 500 
mM imidazole, purified by gel filtration FPLC (Superdex-200; Amersham Pharmacia 
Biotech), and concentrated with an Amicon concentrator (Millipore). Proteins were stable 
for up to 2 weeks at 4°C in 50 mM Tris-HCl, pH 8.0 with 150 mM NaCl, 1 mM PMSF, 
and 1 mM EDTA. 
Five different mutant forms of huntingtin exon 1 were successfully purified, ranging from 
16 glutamines (normal) to 72 glutamines (juvenile Huntington’s disease). Using a new 
lysis protocol involving sonication rather than osmotic shock, yields were increased from 
1-2 mg/L to 10-15 mg/L for huntingtin with 16 glutamines. Additionally, this new protocol 
allowed for purification of huntingtin with 72 glutamines, which had not been successfully 
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purified previously. 
 
2. Assay Development to Measure Huntingtin Aggregation 
2.1 Thioflavin T (ThT) Assay for Amyloid Formation 
Thioflavin T (ThT) is a dye that is widely used to visualize and quantify amyloid in 
Alzheimer’s disease patients and in experiments on amyloid beta [89]. When ThT binds 
to structures that are rich in β sheets, such as in amyloid aggregates, the dye has an 
enhanced fluorescence signal that is thought to be caused by changes in charge 
distribution upon binding to highly ordered amyloid structure [90]. In initial experiments 
on ThT interaction with huntingtin exon 1, constructs were used with only 16 glutamine 
repeats, and no increase in ThT signal was seen. However, when constructs ranging 
from 16 to 72 glutamines were used, a striking correlation of increased ThT signal with 
increased polyQ length was seen (Figure 3-1). This had not been published in the 
literature at the time of the experiment, but was reported shortly after [91]. 
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Figure 3-1. ThT assay on huntingtin exon 1 constructions with a range of polyQ repeats. 
 
2.2 Turbidity Assay 
Turbidity assays were performed by measuring the absorbance of huntingtin exon 1 at 
405 nm on a Nanodrop UV-Vis spectrophotometer before and after enterokinase (EK) 
cleavage of the stabilizing TRX tag. After EK cleavage, the turbidity of the solution 
increased in a polyQ-repeat-length-dependent manner (Figure 3-2). The initial turbidity 
of the HD-46Q protein may be due to aggregation of the protein despite the presence of 
the TRX tag, as well as a small amount of spontaneous cleavage of the tag. The 
apparent aggregation of HD-72Q appears to be lower than for HD-46Q likely because 
the concentration of the HD-72Q protein was approximately half that of the other 
proteins due to difficulty purifying large amounts of this protein. 
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Figure 3-2. Turbidity assay results revealed significant aggregation after cleavage of the 
TRX tag. 
 
2.3 Dynamic Light Scattering 
Dynamic light scattering (DLS) is a technique used to determine the size distribution 
profile of small particles in suspension and is another method that is sensitive to 
aggregate formation. DLS measurements were carried out on a Wyatt DynaPro light 
scattering instrument to obtain size distributions and hydrodynamic radii (Rh). DLS was 
used to observe the aggregation of soluble HD-16Q upon EK cleavage of the stabilizing 
thioredoxin tag (Figure 3-3). 
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Figure 3-3. Cleavage of TRX tag by EK leads to aggregation over 16 hours as 
measured by DLS. 
DLS confirmed the relative absence of aggregates in starting stocks of monomeric 
huntingtin exon 1 peptide, and also tested for the presence of aggregates upon EK 
cleavage. Unfortunately, DLS appears to break down at later stages of aggregation due 
to large particle size and complexity of the aggregate mixture; therefore, meaningful data 
could only be obtained for the first 16 hours post-EK cleavage. 
 
2.4 Congo Red Staining 
Congo red is a dye that has classically been used to indicate the presence of amyloid 
fibrils in histology slides [92]. When congo red-stained preparations are imaged under 
polarized light, apple-green birefringence is indicative of the presence of amyloid fibrils 
[93]. In this experiment, samples of huntingtin exon 1 with 46 glutamines (HD-46Q) were 
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stained after 30 day incubation at 4°C, and also after 3 days of shaking at 37°C. While 
no staining was visible for the huntingtin sample kept at 4°C, some possible congo red 
staining was seen after shaking at 37°C. 
 
Figure 3-4. Congo red staining for presence of amyloid. 
 
3. Huntingtin Crystallization Trials 
Many previous experiments in the Bjorkman lab have been conducted in an attempt to 
crystallize huntingtin, and while several researchers have documented the presence of 
microcrystals, diffraction-quality crystals have never been obtained. 
96-well crystallization trials were set up in the Caltech macromolecular crystallization 
laboratory using the Art Robbins Gryphon Nano, a robot used to set up high-throughput 
crystallization screens. The Rigaku Minstrel was used to automatically take images of 
crystallization plates at given time points; these images were uploaded online for rapid 
access to crystallization hits. Several conditions yielded spherolites or imperfect crystals, 
which were looped using 30% glycerol as a cryoprotectant, frozen in LN2, and sent to 
the Stanford Synchrotron Radiation Laboratory (SSRL) for crystallographic data 
collection on beamline 12-2. However, no diffraction was obtained. 
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Difficulty growing diffraction-quality crystals may be due to lack of strong secondary 
structure in this region or slow aggregation of huntingtin during crystallization. In 2005, 
attempts were made to co-crystallize short polyQ peptides with antibodies known to bind 
huntingtin. The Fv portion of one of these antibodies, MW1, was successfully crystallized 
from a solution containing both a polyQ peptide and MW1 Fv [54]. We proposed that the 
MW1 Fab might assist in crystallization of huntingtin in a similar fashion as the MW1 Fv 
by stabilizing crystal-packing surfaces. 
Additionally, we attempted to crystallize huntingtin exon 1 using the unique environment 
provided by microgravity to increase the crystal quality and size compared to protein 
crystals grown on Earth (further discussed in Chapter 4). During protein crystal growth, 
convection in the solution surrounding growing protein crystals occurs as protein 
molecules from the surrounding solution move and assemble to become part of the 
growing crystal lattice. The movement of proteins toward a crystal and incorporation into 
a growing crystal lattice leads to a lower protein concentration, and a lower relative 
density, in the solution bordering the crystal than in the remainder of the solution. In an 
environment with gravity, the less dense solution has a tendency to rise, while the 
denser solution sinks, which causes convective fluid flow next to the growing crystal. 
These convective currents may have a negative effect on the quality of the crystal being 
formed because they may alter the position of the protein molecules as they become a 
part of the crystal lattice, producing disorder in the crystal lattice. These lattice 
imperfections adversely affect X-ray diffraction and subsequent analysis. However, in a 
microgravity environment, convective fluid flow is greatly reduced, allowing for slow, 
diffusion-driven protein crystal growth [94]. This suggests that microgravity may be an 
ideal environment for growing macromolecular crystals. In fact, previous experiments on 
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the International Space Station (ISS) have shown that reduction in buoyancy-driven 
convection and sedimentation leads to stabilization of growing crystals and more 
organized, larger protein crystals. Since the inception of NASA’s protein crystal growth 
program in the late 1980s, more than 200 different proteins have been flown on Space 
Shuttle missions or on the Russian space station Mir [95]. 
We were encouraged that the X-ray crystal structure of insulin, a protein that significantly 
aggregates over time, and PPG10, a collagen-like protein with a polyproline segment 
similar in sequence to that in the unsolved region of huntingtin exon 1, were both 
successfully crystallized at high resolution aboard the ISS despite relatively poor crystal 
quality on Earth [96-98]. However, only 20-30% of protein crystal growth experiments 
carried out under microgravity have been successful. Differences in mass transport in 
microgravity and experimental setup limitations require that crystal growth conditions be 
optimized. To reduce potential problems with crystal growth, we coordinated with the 
Center for Advancement of Science in Space (CASIS) to evaluate appropriate conditions 
for crystallization of huntingtin. 
We selected a team of engineers at the University of Alabama at Birmingham Center for 
Biophysical Science and Engineering (CBSE) as our service providers due to their 
extensive experience as implementation partners for previous space flight missions. The 
CBSE team provided the engineering, integration, operations, safety, and post-flight 
recovery support for our microgravity research. Additionally, they provided necessary 
documentation and expertise for safety review, toxicology assessments, and 
Certification of Flight Readiness Reviews (CoFR). We used the Hand-Held High Density 
Protein Crystal Growth (HDPCG) crystallization growth cell assembly for our huntingtin 
crystallization studies on the ISS. The HDCPG grows crystals by vapor diffusion and had 
   
 
65
been used successfully in previous ISS crystallography experiments as part of the 
CGCG-H (Commercial Protein Crystal Growth- High Density) and CMPCG (Commercial 
Macromolecular Protein Crystal Growth) studies. The HDPCG requires few crew 
resources, and it is compatible with existing NASA-provided cold stowage facilities. Each 
Hand-Held HDPCG container includes 6 individual HDPCG blocks for a total of 30 
sample wells per hand held device. The CBSE research team provided us with two 
hand-held HDPCG assemblies for space flight, for a total of 60 sample chambers for 
crystallization experiments. Two additional Hand Held HDPCG assembles were provided 
as back up hardware or ground control hardware. An individual well of the HDPCG 
apparatus is pictured below (Fig. 3-5). 
Figure 3-5. HDPCG hardware schematic. Adapted from [99]. 
 
The HDPCG apparatus was oriented in position A (Figure 3A) for launch. In this position, 
the protein solution and precipitant solution were kept separate. On the ISS, 
crewmembers turned the center barrel to position B to allow vapor diffusion between the 
huntingtin protein solution and the precipitant solution, leading to crystal growth (Figure 
3C). Prior to return to Earth, the barrel was returned to position A. Upon return to Earth, 
   
 
66
crystals were harvested from several growth wells. 
  
   
 
67
 
 
 
 
 
 
 
Chapter 4: Comparative Analysis of Anti-Polyglutamine 
Fab Crystals Grown on Earth and in Microgravity 
 
 
  
   
 
68
Chapter 4: Comparative Analysis of Anti-Polyglutamine Fab Crystals Grown on 
Earth and in Microgravity 
1. Abstract 
Huntington’s disease is one of nine neurodegenerative diseases caused by a 
polyglutamine (polyQ) repeat expansion. An anti-polyQ antigen-binding fragment, MW1 
Fab, was crystallized both on Earth and on the International Space Station, a microgravity 
environment where convection is limited. Once the crystals returned to Earth, the number, 
size, and morphology of all crystals were recorded, and X-ray data were collected from 
representative crystals. Results generally agreed with previous microgravity crystallization 
studies. On average, microgravity-grown crystals were 20% larger than control crystals 
grown on Earth (hereafter called ground or control crystals), and microgravity-grown 
crystals had slightly improved mosaicity (decreased by 0.03°) and diffraction resolution 
(decreased by 0.2 Å) compared to ground crystals. However, the highest resolution and 
lowest mosaicity crystals were formed on Earth, and the highest-quality crystal overall was 
formed on Earth after return from microgravity. We determined the 1.8 Å crystal structure 
of MW1 Fab from an Earth-grown crystal, revealing an antigen-binding site that can 
accommodate extended stretches of glutamines.  
 
2. Introduction 
Huntington’s disease (HD) is a progressive, late-onset neurodegenerative disease 
characterized by neuronal death resulting in choreaform movements, cognitive decline, 
and behavioral abnormalities [100]. There currently is no disease-modifying treatment or 
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cure for HD [26]. HD is found in individuals with an abnormally expanded N-terminal 
polyglutamine (polyQ) repeat in huntingtin, a 350 kDa protein of unknown function. The 
length of this polyQ tract influences the mechanisms of aggregation and associated 
binding kinetics, with increasing aggregation propensity with increasing polyQ tract length 
[101]. HD is completely penetrant when the polyQ repeat expands beyond a 37-glutamine 
threshold. However, the mechanism underlying this transition is unclear, and the 
relationship between polyQ-mediated aggregation, cellular toxicity, and HD symptoms has 
not been well characterized. The structure of polyQ with >37Q has been suggested to 
adopt a new β-sheet conformation [61] or a random coil conformation [69]. In the absence 
of an X-ray crystal structure, the nature of the expanded polyQ region and the interactions 
between mutant polyQ and other proteins are unclear. 
The polyQ repeat in huntingtin is recognized by several monoclonal anti-polyQ antibodies, 
including MW1 [45]. Two recent papers measured huntingtin protein in cerebrospinal fluid 
of patients with HD using the MW1 antibody as one of a pair of antibodies in 
immunoprecipitation-flow cytometry [19] or FRET [100]. Information about the three-
dimensional (3-D) structure of MW1 and its interactions with mutant huntingtin could assist 
in development of polyQ-length-based methods for quantitation of huntingtin in patients 
with HD in clinical trials [36]. X-ray crystal structures of the MW1 fragment variable (Fv) 
(the variable heavy and variable light domains; VH and VL) alone (PDB: 2GSG) and in 
complex with a GQ10G peptide (PDB: 2OTU, 2OTW) [54] demonstrated that the polyQ 
epitope could adopt a linear and extended conformation within a shallow groove of the 
MW1 Fv, and also demonstrated that the binding epitope for MW1 encompasses ~10 
glutamines. Major structural changes occurred in MW1 Fv upon polyQ binding, including 
movement of amino acids in the third complementarity determining regions (CDRs) of the 
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heavy and light chain variable domains (CDRH3 and CDRL3) to allow hydrogen bond 
formation between the antigen-binding site and polyQ. 
We previously attempted to crystallize huntingtin alone and complexed with Fabs (antigen 
binding fragments) of anti-polyQ antibodies, including MW1 Fab. While stable complexes 
of Fabs with the polyQ-containing N-terminal domain of huntingtin with 16, 25, 39, and 46 
glutamines (HD-16Q, HD-25Q, HD-39Q, HD-46Q) formed in solution [102], no crystals of 
huntingtin or of a Fab:huntingtin complex could be obtained. Crystallization of the polyQ 
stretch of huntingtin is particularly challenging due to polyQ-length-dependent aggregation 
[103]. 
Reduced gravity environments may improve crystal formation for proteins that have a 
propensity to form a disordered aggregate at high concentrations such as huntingtin due to 
reduction in buoyancy-driven convection. In low convection environments, mass transport 
is primarily driven by diffusion. Aggregates and large impurities diffuse more slowly than 
monomers; therefore, monomers may have greater access to the surface of the growing 
crystal than aggregates in microgravity [104]. Microgravity has led to improved crystal size 
and quality for several proteins including insulin [105, 106], a protein that has been used 
as a model of amyloid formation [107], and PPG10, a collagen-like protein with a 
polyproline region similar to that flanking the polyQ region of huntingtin [96]. To gain 
further insight into the interaction between anti-polyQ Fabs and the polyQ repeat of 
huntingtin, we conducted protein crystallization experiments on the International Space 
Station (ISS); this provided an environment where protein crystals could grow undisturbed 
for several months in a microgravity environment. Crystallization studies in microgravity 
and parallel ground control tests were designed to examine whether we could generate 
high quality crystals of polyQ proteins, or crystals of a polyQ-containing protein in complex 
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with anti-polyQ Fabs. We were unable to generate crystals of poly-Q containing proteins 
on the ISS or in ground controls, but present here a comparative analysis of MW1 Fab 
crystals grown in microgravity and on Earth. 
 
3. Methods 
3.1. Protein expression and purification 
MW1 Fab was purified as previously described [102]. Briefly, MW1 Fab was prepared by 
papain cleavage of MW1 IgG and protein A affinity chromatography (GE Healthcare, 
Little Chalfont, United Kingdom), with further purification by size-exclusion 
chromatography (SEC) (Superdex 200 10/300 GL) (Fig. S1). Purified protein was stored 
at 4°C in 50 mM Tris (pH 8.0) and 150 mM NaCl for up to three months. Other proteins 
used in our microgravity crystallization trials included human huntingtin exon 1-
thioredoxin (TRX) fusion proteins (HD-16Q, HD-25Q, HD-39Q, HD-46Q) [58, 102], GFP-
huntingtin [108], and the Fab from an MW1-related antibody called 3B5H10 [62]. The 
GFP-huntingtin construct was the gift of Dr. Robert Hughes (Buck Institute, Novato, CA). 
Each of these proteins was purified using Ni2+-NTA affinity chromatography (GE 
Healthcare) and SEC (Superdex 200 10/300 or 16/60), flash frozen, and stored at -80 °C 
in 50 mM Tris (pH 8.0) and 150 mM NaCl, with the exception of GFP-huntingtin which 
was stored at -80 °C in 10 mM HEPES (pH 7.5), 50 mM NaCl, 10% glycerol, and 0.5 mM 
TCEP (tris(2-carboxyethyl)phosphine), a reducing agent. Purified full-length huntingtin 
protein [43] was the gift of Dr. IhnSik Seong (Massachusetts General Hospital) and was 
stored at -80 °C in 50 mM Tris (pH 8.0) and 100 mM NaCl. Protein concentrations were 
determined using 280 nm extinction coefficients of 78,310 M-1 cm-1 (MW1 Fab), 80,830 
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M-1 cm-1 (3B5H10 Fab), 14,180 M-1 cm-1 (HD-16Q, HD-25Q, HD-39Q, and HD-46Q), and 
22,015 M-1 cm-1 (GFP-huntingtin). Extinction coefficients were calculated based on 
amino acid sequence using ProtParam [109]. A bicinchoninic acid (BCA) assay (Thermo 
Scientific, Rockford, IL) was used to determine total protein concentration of full-length 
huntingtin. 
For crystallization of MW1 Fab alone, the protein was concentrated to 7 mg/mL in a 
centrifugal filter (EMD Millipore, Darmstadt, Germany). For MW1 Fab:HD-39Q co-
crystallization trials, purified MW1 Fab and HD-39Q were incubated at a 3:1 molar ratio 
for at least 1 hr at 4°C. Crystallization conditions were optimized on Earth prior to 
microgravity experiments. Initial concentrations for all proteins are listed in Table S1. 
 
3.2. Vapor diffusion crystallization 
Vapor diffusion protein crystal growth experiments in microgravity were performed using 
the Hand-Held High Density Protein Crystal Growth (HDPCG) hardware (Fig. 1a) 
developed by the Center for Biophysical Sciences and Engineering at the University of 
Alabama, Birmingham. The Handheld HDPCG hardware was designed to reproduce a 
sitting or hanging drop crystallization experiment in a microgravity environment [110], and 
it has been used to crystallize dozens of proteins on the Space Shuttle or ISS [111-113]. 
Each aluminum Handheld HDPCG hardware unit held five HDPCG sample blocks (Fig. 
1b), which were molded from Zeonor plastic. Each sample block consisted of six individual 
growth cells that each contained a single vapor diffusion crystal growth experiment (Fig. 
1c). Each growth cell was isolated by triple O-ring containment. 
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For preparation of experiments prior to launch, 2.5 µL of protein solution was mixed with 
an equal volume of precipitant solution and placed in a 5 µL well in a growth cell. A 
separate reservoir in the same growth cell was loaded with ~500 µL precipitant solution at 
the desired final concentration. The precipitant solution was immobilized in the reservoir 
using an insert made of chromex, a porous absorbent material composed of ultra high 
molecular weight polyethylene (Porex, Fairburn, GA). A total of 120 crystallization 
experiments were set up, 60 for microgravity experiments and 60 replicates as ground 
controls. Initial conditions for all experiments are listed in Table S1. After all solutions were 
loaded, each well was checked to ensure there were no bubbles, and the sample blocks 
were then sealed. Ten HDPCG sample blocks total were loaded into two Handheld 
HDPCG hardware units. To prevent movement or mixing of solutions prior to or during 
launch, the sample block barrels were rotated 90° clockwise to “launch configuration” (Fig. 
1d). 
For experiment activation in-orbit, an astronaut rotated the sample block barrels another 
90° clockwise using an Activation Tool (silver object in Fig. 1a) to establish an air path 
between the protein solution in the well and the precipitant solution in the reservoir (Fig. 
1e). After activation, the experiments were stored undisturbed on the ISS. Initially, the 
protein solution contained an insufficient concentration of precipitant for crystallization, but 
as water vaporized from the droplet and transferred to the reservoir, the precipitant 
concentration in the protein well increased to an optimal level for crystallization in some 
experiments. Before return to Earth, an astronaut resealed the experiment by using the 
Activation Tool to rotate the sample block barrel counterclockwise 90° to “launch 
configuration” to turn the protein inserts away from the precipitant reservoir. 
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3.3. Timeline 
All protein and precipitant stock solutions were prepared 7-52 days before launch. 
Proteins, precipitant solutions, and other equipment were transported to the Space Station 
Processing Facility, Kennedy Space Center (KSC), Florida between March 9 and April 10, 
2014. Proteins were maintained at -20 °C (HD-16Q, HD-25Q, HD-39Q, HD-46Q, GFP-
huntingtin, full-length huntingtin) or 4 °C (MW1 Fab, 3B5H10 Fab) during transport and 
storage. Before launch, flight HDPCG growth cells were prepared at 4 °C in a cold room 
previously used for astronaut food storage. HDPCG sample filling and hardware 
integration was completed on April 16, 2014 (Fig. 2). The HDPCG hardware units were 
turned over to Cold Stowage for integration on April 17, 2014 and were installed at 4 °C on 
the same day in a Double Cold Bag, a Nomex bag with vacuum insulation panels for 
passive thermal insulation [114]. Phase-change material Ice Bricks were added to the 
Double Cold Bag to maintain a 4 °C environment for the HDPCG hardware units prior to 
launch and during ascent to the ISS. Due to specific problems immediately before a 
launch, all experimental materials were prepared repeatedly for launch prior to the 
successful launch on April 18, 2014. 
A total of 60 crystallization experimental trials in two Handheld HDPCG hardware units 
were launched from Cape Canaveral, Florida in an unmanned SpaceX-3 supply vehicle on 
April 18, 2014 at 15:25 Eastern Daylight Time (EDT). The Dragon capsule berthed with 
the ISS on April 21, 2014, the units were transferred to the ISS, and activation was 
completed at 07:50 EDT. After activation, the experiments were placed in a Minus Eighty 
Laboratory Freezer for ISS (MELFI) at 2 °C. Crystals were allowed to grow undisturbed in 
microgravity for exactly 6 months (183 days). The CASIS PCG hardware remained in the 
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MELFI until just prior to unberth of SpaceX-4. HDPCG deactivation and transfer to a 
Double Cold Bag at 4 °C for return was completed at 15:00 EDT on October 20, 2014. 
The deactivated experiments descended to Earth on October 25, 2014 in SpaceX-4. The 
Dragon capsule landed in the Pacific Ocean on October 25, 2014 at 15:38 EDT, and the 
experiments were handed over for transfer to Caltech in Pasadena, California at 18:30 
EDT on October 26, 2014. A temperature of 4±2 °C was maintained during all transport 
operations. The HDPCG hardware units were stored and imaged, and crystals were 
harvested, in a 4 °C room. There were no pre-flight, in-flight, or post-flight anomalies. 
 
3.4. Ground control and comparison studies 
The results of the microgravity crystallization experiments were evaluated using the best 
crystals that could be grown in identical conditions to the space flight experiments, termed 
“ground controls.” Ground controls to replicate the conditions in the space flight 
experiments were set up at 4 °C at Caltech in HDPCG sample blocks with identical 
purified proteins, buffers, and precipitant solutions as used for the microgravity payload, 
with a seven day delay compared to flight experiments. 
 
3.5. Crystal number, size and morphology analysis 
Immediately upon return from the ISS, bright field images of all microgravity crystallization 
wells were taken at 40X magnification on an Olympus SZX16 microscope (Olympus 
Corporation, Tokyo, Japan) using a Canon DS126311 EOS Rebel camera (Canon Inc., 
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Tokyo, Japan). The ground control wells also were imaged, with an approximate seven 
day delay. Fiji [115] was used to measure the long axis and short axis of each crystal 
using the line tool. The area of each crystal was calculated both by multiplying the long 
and short axis, and by either the polygon selection tool or freehand selection tool based on 
crystal shape. A MicroRulerTM (MiTeGen, Ithaca, NY) was used to scale images in 
microns. Crystal number, morphology, and visible area were recorded. Morphology was 
judged by the sharpness of crystal edges and shape of the crystal. Crystals were 
photographed again five months after return to Earth to evaluate changes in crystal size 
and morphology. 
After crystals were harvested for X-ray diffraction data collection, the remaining crystals 
were imaged with a Korima PRS-1000 UV microscope (Korima Inc., Carson, CA) at 25 °C 
to distinguish protein crystals from salt crystals based on tryptophan fluorescence under 
UV light. Representative bright field and UV images of wells containing protein crystals are 
shown in Figs. S1 and S2, respectively. Some small crystals seen with UV microscopy 
were not visible using bright field microscopy; size and X-ray diffraction data were not 
collected for these crystals. 
 
3.6. Crystallographic data collection, structure determination and refinement 
Protein crystals were removed from HDPCG sample wells and briefly soaked in mother 
liquor solution supplemented with 7.5%, 15%, and then 30% glycerol before flash cooling 
in liquid nitrogen. X-ray diffraction data were collected from 155 total representative 
microgravity-grown and Earth-grown crystals at the Stanford Synchrotron Radiation 
Lightsource (SSRL) beamline 12-2 using a Pilatus 6M pixel detector (Dectris). X-ray 
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diffraction data sets were collected for 32 crystals. X-ray diffraction data were unobtainable 
for some small crystals grown in microgravity due to technical limitations. The collected 
data sets were indexed, integrated, and scaled using XDS, a crystallographic data 
processing program [116, 117]. 
Data quality was analyzed using XDS and the PHENIX crystallography package [118]. 
Overall resolution limits of each dataset were estimated using I/σI > 1.50 as well as CC1/2 
(correlation coefficient between two random halves of the data set) [119], where CC1/2 > 
0.3. Average mosaicity was determined using the scaling program AIMLESS [120]. 
 
4. Results 
4.1. MW1 Fab crystals formed in microgravity had increased size and decreased 
abundance compared to crystals grown on Earth, while morphology remained similar. 
Crystals formed in several wells both in microgravity and on Earth. All crystals formed in 
wells containing MW1 Fab alone or MW1 Fab with HD-39Q. No crystals were observed in 
any wells containing full-length huntingtin or GFP-huntingtin; instead, the presence of UV-
fluorescent aggregate was noted in these wells. Crystals were observed in 10 of 60 wells 
in the microgravity HDPCG wells, and 9 of 60 wells in the ground control HDPCG wells 
(Fig. 3b, Table 1). Of the wells containing crystals, one was found only in the flown 
samples, i.e., there were no crystals in the corresponding ground control well. This well 
contained needle crystals that did not diffract beyond 5 Å. No crystals were observed in 
the ground control wells without also being observed in the sample wells in the flown 
HDPCG growth cells. 
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The morphologies of crystals tended to be similar in microgravity and corresponding 
ground control wells. Most crystals had sharp edges, although several wells contained 
crystals with plate or needle morphologies (Fig. 3a). In wells 1 and 2, crystals grew larger 
and were thicker than in parallel ground control wells (Fig. S2). Also, in well 29, ground 
control samples grew only microcrystals from which no diffraction data could be collected, 
while crystals were larger in the ISS samples, and diffraction data could be recorded. 
Conversely, crystals in well 35 grew larger on Earth than in microgravity, demonstrating 
that the size effect was not consistent between microgravity and Earth conditions. 
Microgravity-induced changes in crystal morphology have been previously reported [121-
124]; however, the morphologies seen in our experiments have all been seen previously 
for the analogous crystals on Earth and did not represent new crystal forms. 
Quantitative analyses of crystal number and visible crystal area from microscopy images 
demonstrated that significantly fewer crystals of a size suitable for diffraction (> 20 µm in 
each dimension) were grown per well in microgravity compared with ground controls (Fig. 
3b, Table 1). To our knowledge, this is the first microgravity study to statistically analyze 
differences in crystal size. Two wells in each condition formed microcrystalline precipitate, 
microcrystals, or stacks of needle crystals; these crystals were not included in crystal 
number and size analysis, which could have changed the data dramatically. Microgravity 
well 10 contained a large stack of needle crystals (~250 crystals) that could not be 
accurately counted, and microgravity well 35 had ~3,000 microcrystals that were below the 
threshold of 20 µm in each visible dimension In ground controls, well 29 contained ~46 
microcrystals, and well 30 contained ~230 microcrystals; these also were not part of the 
analysis. 
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Analyses of the visible crystal area showed that crystal size was larger in microgravity 
(Fig. 3b, Table 1). The largest microgravity-grown crystal was larger than the largest 
ground control crystal. This agrees with previous reports of increased crystal size and 
decreased crystal number in microgravity [111]. Convection on Earth may increase the 
rate of nucleation in solutions containing crystals that are growing, termed secondary 
crystal nucleation, due to flow of partially nucleated proteins from growing crystal surfaces 
[125]. Increased secondary nucleation would theoretically yield more and smaller crystals 
in Earth compared to microgravity. 
We recorded images of crystals immediately upon receipt of experiments from the ISS, but 
no photographs of crystals could be taken on-orbit during microgravity crystal growth due 
to incompatibility of current ISS microscope hardware with the HDPGC growth cells, 
particularly due to the variable opacity of the chromex insert. To keep ground controls 
matched to microgravity experiments, ground controls also were not imaged during the 
six-month duration of the experiment. Thus, the optimal time for crystal nucleation and 
growth in microgravity is unclear. A different time frame may have produced more crystals. 
Additionally, we found that crystals grew several months after return to Earth in two wells 
sent to the ISS that did not contain visible crystals upon initial return to Earth, and 3-D 
crystal growth also occurred in one well that had only irregularly-shaped crystals upon 
initial return to Earth. This was confirmed by analysis of the second set of images taken of 
all crystallization wells five months after the experiment returned to Earth. Although crystal 
nucleation may have taken place on the ISS, we have categorized these as “ground” 
crystals because most crystal growth occurred in a 1g environment. These ground crystals 
were not included in morphology, size, or number analyses, but X-ray diffraction data were 
collected for several of these crystals. To our knowledge, this is the first microgravity 
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experiment that has reported crystal growth post-flight. 
3.2. Microgravity-grown crystal showed improved X-ray diffraction resolution on average, 
but the highest resolution and lowest mosaicity crystals grew on Earth 
DDiffraction from microgravity and ground crystals was evaluated for resolution limit and 
mosaicity. High resolution is desirable to allow interpretation of the chemical details of a 
protein structure. Mosaicity is defined as the full width at half maximum of diffraction 
peaks. High average mosaicity values are a sign of a poorly ordered crystal and are 
generally undesirable because wider diffraction maxima can result in overlapping 
reflections. 
MW1 Fab crystals were obtained in three space groups (Table 2). Crystals of MW1 Fab 
(space group P21, a = 42 Å, b = 72 Å and c = 89 Å; β = 91°; one molecule per asymmetric 
unit) were obtained upon mixing MW1 Fab at 7 mg/mL with 0.1 M sodium citrate tribasic 
dihydrate (pH 5.0) and 18% w/v PEG 20,000. This condition yielded crystals that diffracted 
to 1.6-2.3 Å, the highest resolution of any MW1 Fab crystals. These crystals formed after 
return from the ISS. Crystals that diffracted to 3.0 Å were obtained in this space group and 
unit cell by mixing MW1 Fab at 7 mg/mL plus HD-16Q at 7 mg/mL with 0.2 M magnesium 
chloride hexahydrate, 0.1 M sodium citrate tribasic dihydrate (pH 5.0) and 10% w/v PEG 
20,000, at 4 °C, also in a well where crystal formation occurred after return from the ISS. 
Crystals did not form in microgravity or in ground controls in space group P21, so the 
effects of microgravity on MW1 Fab crystals in this space group is unclear. For all crystals 
grown in the presence of an HD protein, only MW1 Fab crystallized. 
Crystals of MW1 Fab in a second space group (P212121, a = 44 Å, b = 55 Å and c = 299 Å; 
one molecule per asymmetric unit) were obtained upon mixing MW1 Fab at 7 mg/mL plus 
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HD-39Q with one of four precipitant solutions at 4 °C: 0.1 M sodium acetate trihydrate (pH 
4.5), and 30% w/v PEG 300; 1.8 M ammonium sulfate, 0.1 M BIS-TRIS (pH 6.5) and 2% 
v/v PEG MME 550; 0.2 M magnesium chloride hexahydrate, 0.1 M sodium citrate tribasic 
dihydrate (pH 5.0), and 14% w/v PEG 20,000; or 0.2 M magnesium chloride hexahydrate, 
0.1 M sodium citrate tribasic dihydrate (pH 5.0), and 18% w/v PEG 20,000. Over 70% of 
crystals that formed in microgravity or ground control wells that diffracted to beyond 5.0 Å 
were in this space group and unit cell. The highest resolution crystals in this space group 
were formed in ground controls; however, the average resolution improved by 0.2 Å and 
the average mosaicity of the diffraction data decreased by 0.03° in microgravity wells 
compared to ground control wells. If the analysis is limited to only crystals that were 
looped immediately upon return from the ISS, the average resolution improved by 0.4 Å 
and mosaicity decreased by 0.07° in microgravity wells compared to ground control wells. 
This is consistent with previous findings of improvements of 0.2-0.4 Å resolution for 
crystals grown in microgravity compared with ground control crystals [126]. 
Crystals of MW1 in a third space group (P622, a = 189 Å, b = 189 Å and c = 64 Å; γ = 
120°; one molecule per asymmetric unit) were obtained upon mixing MW1 Fab at 7 mg/mL 
with 0.1 M sodium citrate tribasic dihydrate (pH 5.5), 16% w/v PEG 8,000 or 0.1 M sodium 
citrate tribasic dihydrate (pH 5.0) and 18% w/v PEG 20,000 at 4 °C. Crystals formed both 
in microgravity and in ground controls in this space group; however, the resolution was 
poor for all diffracting crystals, ranging from 3.2 Å to >8 Å. The highest resolution crystals 
were formed in microgravity, with an improvement of 0.8 Å in resolution and a decrease of 
0.07° in mosaicity for the highest resolution microgravity crystal in this space group 
compared to the highest resolution ground control crystal in the same space group. 
Previous studies have addressed whether particular space groups are more amenable to 
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crystallization in a convection-free environment, and found that no space group appeared 
to be more amenable to improvement in microgravity [95]. Our data support this 
conclusion. 
 
5. Discussion 
Microgravity affects crystal growth by preventing sedimentation and decreasing buoyancy-
driven forces on the crystal, thereby creating a more stable depletion zone around a 
growing crystal [127]. Through these mechanisms, microgravity-grown crystals have been 
reported to have increased resolution, decreased mosaicity, and increased crystal volume 
compared to Earth-grown controls [128, 129]; however, some negative studies have been 
published, and the benefit of microgravity crystallization has been fiercely debated [130] 
since the first microgravity crystallization experiment [131]. In our studies, we found 
microgravity-grown crystals of MW1 Fab showed a slight increase in size and an 
improvement in resolution and mosaicity when compared to Earth-grown crystals in one 
space group in agreement with some published results [132, 133]; however, the highest 
overall resolution X-ray data were obtained from a crystal grown on Earth. 
Improvements in crystal volume in microgravity are driven by two factors: 1) decreased 
sedimentation, leading to fewer fused aggregates and increased uniformity of crystals [95], 
and 2) Maragoni convection and transient accelerations, which also promote increases in 
crystal volume under microgravity conditions, despite possible deleterious effects on 
crystal packing [124, 134, 135]. Marangoni convection arises in vapor diffusion 
experiments, and occurs at the phase boundary between the concentrated solution of 
protein and the air. Concentration gradients that form during crystallization or precipitation 
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result in differences in surface tension, which lead to different rates of transfer of vapor at 
the surface of the protein drop. While Marangoni convection is not the predominant 
method of mass transfer in crystallization experiments on Earth, it becomes an important 
factor when buoyancy-induced convection is substantially reduced in microgravity [134]. 
An analysis of microgravity experiments found greater improvements in crystal quality in 
liquid-liquid diffusion experiments compared to vapor diffusion experiments [95], and may 
have been a factor in our microgravity vapor diffusion experiments. Additionally, transient 
accelerations on the ISS, such as residual accelerations from crew movement and 
exercising, vibrations imposed by equipment operating near crystallization experiments, 
and vehicle accelerations from reboost or collision avoidance maneuvers (CAMs), could 
have also led to deviation from a true microgravity environment. In a perfect microgravity 
environment, crystal nucleation occurs but growth is slowed because nutrients are 
depleted in the area of the crystal-solution interface. Brief accelerations could stir the 
solution to replenish nutrients around the crystal to help it grow larger. On the Space 
Shuttle, continuous visual feedback on the crystal growth has been used to correlate 
increased crystal growth with increases in transient accelerations [135]; no similar studies 
have been published for microgravity crystallization experiments on the ISS. We found that 
microgravity increased mean MW1 Fab crystal size, although this effect was small. 
In contrast with crystal size, resolution improvements in microgravity are due to improved 
short-range order within a crystal, while mosaicity improvements are driven by improved 
long-range order; both of these are caused by reduction in buoyancy-driven convection. 
Marangoni convection is a limiting factor in these improvements. The combination of these 
effects is complex. 
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In parallel with our microgravity experiments, we analyzed possible alternatives to 
microgravity crystallization. The Grashof number (Gr) describes the relationship between 
inertial and viscous forces, and gives insight into the parameters such as gravity that 
determine the movement of solutions around a growing crystal: 
Gr =   𝜌𝑈!𝐿!𝜂   
where ρ is density, Ub is a measure of buoyant velocity dependent on gravity and 
concentration gradient, L0 is length, and η is shear viscosity [136]. When Gr is small, the 
inertial forces are small compared to viscous forces, and fluid interfaces spread by 
diffusion. Gr is decreased in microgravity, but other environments also decrease 
convection, e.g., increased shear viscosity through use of agarose gels [137] or high 
molecular weight polyethylene glycol (PEG) [138]; decreased length through use of 
microfluidics, or even magnets [139]. Several proteins have been crystallized in a 
centrifuge under hypergravity [140] to nucleate crystals at low concentrations of 
precipitants. However, our experiments to crystallize huntingtin within gels and microfluidic 
crystallization trays did not improve crystallizability (data not shown). 
While our experiments show that ISS is a potential platform for crystal growth, 
crystallization of proteins in space remains a challenge. Given the expense and time 
involved in crystallization trials in microgravity, future experiments should consider the 
potentially deleterious effects of Marangoni convection on vapor diffusion crystallization 
experiments. Additionally, a comparison of microgravity-grown crystals with the best 
crystals obtainable through ground-based methods is necessary to realistically determine 
the relative value of microgravity protein crystallization. 
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6. Figures 
 
Fig. 1. Schematics of the HDPCG device used for microgravity crystallization experiments: 
a) Handheld HDPCG assembly, b) HDPCG sample block, c) HDPCG growth cell in 
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loading configuration, d) HDPCG growth cell in launch configuration, e) HDPCG growth 
cell in microgravity crystal growth configuration. 
 
 
Fig. 2. Timeline of microgravity experiments. 
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Fig. 3. Comparison of crystal morphology and size. Protein crystals grew in both 
microgravity and ground control conditions. a) Morphology of crystals and number of wells 
containing crystals. b) Area of crystals greater than 400 µm2 grown in microgravity (n=67) 
and Earth (n=97). Data shown are geometric means with 95% confidence intervals. The 
geometric mean is suitable for data that range over several orders of magnitude [141]. 
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Fig S1. Representative crystal images taken using bright field microscopy immediately 
upon completion of experiment. 
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Fig S2. Representative crystal images taken using UV microscopy 10 months after 
completion of experiment. 
 
7. Tables 
 
Table 1. Comparison of crystal number and size. 
 
Table 1.
Environment of 
crystals
Number of wells 
with crystals
Average number of 
crystals per well* 
(range)
Mean crystal 
area** (µm2)
Largest crystal 
(µm2)
Microgravity 10 7 (5-13) 1,840 42,700
Ground control 9 14 (1-49) 1,500 27,200
**Geometric mean area
Comparison of crystal number and size.
*Average number of crystals > 400 µm2 per well containing crystals
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Table 2. X-ray data processing statistics for MW1 Fab crystals < 5.0 Å. <I/σ(I)> is the 
empirical signal to noise ratio [119]. 
 
Table 2.
CC1/2 > 0.3 <Ī/σ(Ī)> > 1.50
Microgravity 29 2.47 2.68 0.08 42.10, 71.20, 207.72, 90, 90, 90 P 21 21 21
Microgravity 34 2.55 2.67 0.13 42.35, 71.31, 207.31, 90, 90, 90 P 21 21 21
Microgravity 34 2.57 2.71 0.07 42.36, 71.38, 207.31, 90, 90, 90 P 21 21 21
Microgravity 34 2.58 2.68 0.13 42.59, 71.60, 208.37, 90, 90, 90 P 21 21 21
Microgravity 29 2.63 2.83 0.07 41.98, 71.63, 207.64, 90, 90, 90 P 21 21 21
Microgravity 34 2.63 2.81 0.18 42.60, 71.55, 208.62, 90, 90, 90 P 21 21 21
Microgravity 29 2.67 2.68 0.11 42.05, 71.39, 207.72, 90, 90, 90 P 21 21 21
Microgravity 1 3.20 3.35 0.12 189.07, 189.07, 64.37, 90, 90, 120 P 6 2 2
Ground* 2 1.59 1.71 0.06 42.28, 71.62, 89.19, 90, 91.51, 90 P 21
Ground* 2 1.65 1.80 0.26 42.21, 72.19, 89.92, 90, 91.95, 90 P 21
Ground* 2 1.72 1.80 0.19 42.19, 71.53, 89.08, 90, 90.96, 90 P 21
Ground* 2 1.87 2.03 0.09 42.23, 71.69, 89.05, 90, 91.39, 90 P 21
Ground* 2 2.19 2.32 0.06 42.19, 71.61, 88.88, 90, 91.34, 90 P 21
Ground* 2 2.29 2.61 0.08 42.26, 71.70, 89.04, 90, 91.59, 90 P 21
Ground* 17 3.00 3.00 0.15 42.48, 72.37, 89.78, 90, 91.43, 90 P 21
Ground control 27 1.98 2.25 0.10 41.84, 70.28, 206.78, 90, 90, 90 P 21 21 21
Ground control 27 2.13 2.45 0.06 41.94, 70.43, 207.36, 90, 90, 90 P 21 21 21
Ground control 27 2.40 2.69 0.05 42.03, 70.50, 207.82, 90, 90, 90 P 21 21 21
Ground control 35 2.72 2.88 0.07 42.35, 71.30, 207.37, 90, 90, 90 P 21 21 21
Ground control 35 2.76 2.90 0.15 42.31, 71.20, 207.30, 90, 90, 90 P 21 21 21
Ground control 35 2.76 2.95 0.34 42.37, 71.10, 208.32, 90, 90, 90 P 21 21 21
Ground control 35 2.84 2.96 0.17 42.63, 71.78, 208.79, 90, 90, 90 P 21 21 21
Ground control 27 2.89 2.98 0.16 42.22, 71.01, 208.95, 90, 90, 90 P 21 21 21
Ground control 35 2.91 2.96 0.28 42.38, 71.29, 207.61, 90, 90, 90 P 21 21 21
Ground control 27 3.96 3.70 0.06 41.90, 70.43, 207.75, 90, 90, 90 P 21 21 21
Ground control 2 4.05 4.54 0.19 190.64, 190.64, 64.91, 90, 90, 120 P 62 2 2
Ground control 1 4.33 4.07 0.29 323.00, 63.74, 186.24, 90, 90, 90 P 21 21 21
Cell Dimensions: a, b, c (Å), α, β, γ (°) Space group
*Visible crystals grew in microgravity wells after return from ISS
X-ray data processing statistics for MW1 Fab crystals < 5.0 Å.
Overall Resolution Limit (Å)Environment of 
Crystals Well
Average 
Mosaicity
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Table S1. Initial conditions for all microgravity crystallization experiments. 
Table S1.
Well Protein Name(s)
Protein 
Conc 
(mg/mL)
Crystallization solution
1 MW1 Fab 7 0.1 M Sodium citrate tribasic dihydrate, pH 5.5, 16% w/v PEG 8,000
2 MW1 Fab 7 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 18% w/v PEG 20,000
3 MW1 Fab 7 0.2 M Ammonium citrate tribasic, pH 7.0, 0.1 M Imidazole, pH 7.0, 20% w/v PEG MME 2,000
4 3B5H10 Fab 7 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 10% w/v PEG 20,000
5 3B5H10 Fab 7 1.8 M Ammonium sulfate, 0.1 M BIS-TRIS, pH 6.5, 2% v/v PEG MME 550
6 3B5H10 Fab + K2Q10K2 7 + 7 1.8 M Ammonium sulfate, 0.1 M BIS-TRIS, pH 6.5, 2% v/v PEG MME 550
7 MW1 Fab + K2Q10K2 7 + 7 0.1 M Imidazole, pH 7.0, 30% w/v PEG MME 550
8 MW1 Fab + K2Q10K2 7 + 7 0.2 M Imidazole, pH 7.0, 28% w/v PEG MME 550
9 MW1 Fab + K2Q10K2 7 + 7 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 10% w/v PEG 20,000
10 MW1 Fab + K2Q10K2 7 + 7 0.1 M Imidazole, pH 7.0, 12% w/v PEG 20,000
11 HD-16Q 5 0.1 M Tris-HCl, pH 8.5, 8% w/v PEG 8,000
12 HD-16Q 5 0.1 M Tris-HCl, pH 8.5, 8% w/v PEG 8,000
13 3B5H10 Fab + HD-16Q 7 + 7 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 10% w/v PEG 20,000
14 3B5H10 Fab + HD-16Q 7 + 7 0.1 M Tris-HCl, pH 8.0, 30% v/v Jeffamine M-600, pH 7.0
15 3B5H10 Fab + HD-16Q 7 + 7 0.1 M Sodium acetate trihydrate, pH 4.0, 10% w/v PEG 4,000
16 3B5H10 Fab + HD-16Q 7 + 7 0.25 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 15% w/v PEG 20,000
17 MW1 Fab + HD-16Q 7 + 7 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 10% w/v PEG 20,000
18 MW1 Fab + HD-16Q 7 + 7 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 18% w/v PEG 20,000
19 MW1 Fab + HD-16Q 7 + 7 0.1 M Imidazole, pH 7.0, 25% w/v PEG MME 550
20 MW1 Fab + HD-16Q 7 + 7 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 30% Jeffamine ED-2001 pH 7.0
21 MW1 Fab + HD-16Q 7 + 7 0.1 M BIS-TRIS, pH 6.5, 20% w/v PEG 1,500
22 MW1 Fab + HD-16Q 7 + 7 0.1 M Tris-HCl, pH 8.0, 28% w/v PEG 4,000
23 3B5H10 Fab + HD-39Q 7 + 2.3 0.1 M Sodium acetate trihydrate, pH 4.0, 15% w/v PEG 400
24 3B5H10 Fab + HD-39Q 7 + 2.3 0.1 M Sodium acetate trihydrate, pH 4.0, 15% w/v PEG 400
25 3B5H10 Fab + HD-39Q 7 + 2.3 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 18% w/v PEG 20,000
26 3B5H10 Fab + HD-39Q 7 + 2.3 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 18% w/v PEG 20,000
27 MW1 Fab + HD-39Q 7 + 2.3 0.1 M Sodium acetate trihydrate, pH 4.5, 30% w/v PEG 300
28 MW1 Fab + HD-39Q 7 + 2.3 0.1 M Sodium acetate trihydrate, pH 4.5, 30% w/v PEG 300
29 MW1 Fab + HD-39Q 7 + 2.3 1.8 M Ammonium sulfate, 0.1 M BIS-TRIS, pH 6.5, 2% v/v PEG MME 550
30 MW1 Fab + HD-39Q 7 + 2.3 0.2 M Magnesium formate dihydrate, 0.1 M Sodium acetate trihydrate, pH 4.0, 18% w/v PEG MME 5,000
31 MW1 Fab + HD-39Q 7 + 2.3 0.1 M Sodium citrate tribasic dihydrate, pH 5.5, 18% w/v PEG 3,350
32 MW1 Fab + HD-39Q 7 + 2.3 0.1 M Sodium citrate tribasic dihydrate, pH 5.5, 16% w/v PEG 8,000
33 MW1 Fab + HD-39Q 7 + 2.3 2% w/v 1,4-Dioxane, 0.1 M Tris-HCl, pH 8.0, 15% PEG 3,350
34 MW1 Fab + HD-39Q 7 + 2.3 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 14% w/v PEG 20,000
35 MW1 Fab + HD-39Q 7 + 2.3 0.2 M Magnesium chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.0, 18% w/v PEG 20,000
36 MW1 Fab + HD-39Q 7 + 2.3 0.4 M Sodium malonate, pH 6.0, 0.1 M MES monohydrate, pH 6.0, 0.5% w/v PEG 10,000
37 HD-16Q 10 0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.5, 30% w/v PEG 4,000
38 HD-16Q 10 0.2 M Magnesium acetate tetrahydrate, 0.1 M Sodium cacodylate trihydrate, pH 6.5, 20% w/v PEG 8,000
39 HD-16Q 10 0.5 M Ammonium sulfate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.6, 1.0 M Lithium sulfate monohydrate
40 HD-16Q 10 0.2 M Magnesium chloride hexahydrate, 0.1 M Tris-HCl, pH 8.5, 25% w/v PEG 3,350
41 HD-25Q 10 0.01 M Nickel (II) chloride hexahydrate, 0.1 M Tris-HCl, pH 8.5, 20% w/v PEG MME 2,000
42 HD-25Q 10 0.01 M Nickel (II) chloride hexahydrate, 0.1 M Tris-HCl, pH 8.5, 1.0 M Lithium sulfate monohydrate
43 HD-25Q 10 1.0 M Imidazole, pH 7.0
44 HD-25Q 10 0.1 M BIS-TRIS, pH 6.5, 20% w/v PEG MME 5,000
45 HD-39Q 10 0.01 M Iron (III) chloride hexahydrate, 0.1 M Sodium citrate tribasic dihydrate, pH 5.6, 10% Jeffamine M-600
46 HD-39Q 10 1.0 M Imidazole, pH 7.0
47 HD-46Q 10 0.2 M Calcium acetate hydrate, 0.1 M Sodium cacodylate trihydrate, pH 6.5, 18% w/v PEG 8,000
48 HD-46Q 10 0.5 M Sodium chloride, 0.01 M Magnesium chloride hexahydrate, 0.01 M Hexadecyltrimethylammonium bromide
49 HTT-GFP 20 0.2 M Zinc acetate dihydrate, 0.1 M Sodium cacodylate trihydrate, pH 6.5, 18% w/v PEG 8,000
50 HTT-GFP 20 0.2 M Zinc acetate dihydrate, 0.1 M Sodium cacodylate trihydrate, pH 6.5, 18% w/v PEG 8,000
51 HTT-GFP 20 0.2 M Zinc acetate dihydrate, 0.1 M Sodium cacodylate trihydrate, pH 6.5, 18% w/v PEG 8,000
52 HTT-GFP 20 0.2 M Lithium sulfate monohydrate, 0.1 M HEPES, pH 6.5, 25% w/v PEG 3,350
53 HTT-GFP 20 0.2 M Lithium sulfate monohydrate, 0.1 M HEPES, pH 6.5, 25% w/v PEG 3,350
54 HTT-GFP 20 0.2 M Lithium sulfate monohydrate, 0.1 M HEPES, pH 6.5, 25% w/v PEG 3,350
55 FL-HTT 0.4 0.1 M Sodium cacodylate trihydrate, pH 6.5, 25% w/v PEG 8000
56 FL-HTT 0.4 0.1 M Sodium cacodylate trihydrate, pH 6.5, 25% w/v PEG 8000
57 FL-HTT 0.4 2.4 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate, pH 4.5
58 FL-HTT 0.4 2.4 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate, pH 4.5
59 FL-HTT 0.4 2.4 M Ammonium sulfate, 0.1 M Sodium cacodylate trihydrate, pH 6.5
60 FL-HTT 0.4 2.4 M Ammonium sulfate, 0.1 M Sodium cacodylate trihydrate, pH 6.5
Initial conditions for all microgravity crystallization experiments.
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Table S2. Crystal morphology. 
 
  
Table S2.
Environment of 
crystals Well Morphology
Microgravity 1 3D
Microgravity 2 Irregular
Microgravity 8 Needle
Microgravity 10 Needle
Microgravity 17 Grew post-flight
Microgravity 27 3D
Microgravity 28 3D
Microgravity 29 3D
Microgravity 30 3D
Microgravity 32 Grew post-flight
Microgravity 34 3D
Microgravity 35 3D
Ground control 1 Irregular
Ground control 2 Needle
Ground control 8 Irregular
Ground control 10 Grew post-flight
Ground control 18 Grew post-flight
Ground control 27 3D
Ground control 28 3D
Ground control 29 3D
Ground control 30 3D microcrystals
Ground control 32 Grew post-flight
Ground control 34 3D
Ground control 35 3D
Crystal morphology
   
 
95
 
 
 
 
 
 
 
 
 
Chapter 5: Development of High-Avidity Anti-PolyQ 
Therapeutics 
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Chapter 5: Development of High-Avidity Anti-PolyQ Therapeutics 
1. Fibronectin III (FN3) Domains 
The soluble, unaggregated, unstructured polyQ stretch currently is a target for design of 
drugs to combat Huntington’s disease [54]. Past drug design studies have focused on 
targeting the expanded polyQ repeat in huntingtin with either high-affinity small 
molecules or with antibodies. However, high-affinity polyQ binding proteins may disrupt 
other proteins that have polyQ repeats that are essential for normal cell function, such as 
transcription factors. 
In order to discriminate between huntingtin with normal versus expanded polyQ repeats, 
we decided to create multivalent binding agents that exhibit high avidity rather than high 
affinity for polyQ stretches. Affinity describes the strength of a single 1:1 interaction 
between a protein and its binding partner, whereas avidity describes the combined, 
synergistic strength of multiple interactions. A well-known example of avidity occurs 
when antibodies bind to antigens that are tethered to a surface– because an antibody 
has two “arms,” it can bind two antigens simultaneously. Thus when a binding interaction 
breaks, the other binding interaction can keep the antibody bound to the antigens on the 
surface. Here we constructed binding complexes with multiple polyQ binding sites that 
bind with high avidity to long polyQ stretches. Our high-avidity binding complex should 
bind only weakly to proteins with a short polyQ stretch, but the complex would bind much 
more strongly to proteins with longer stretches of polyQ (Figure 5-1). Through linking 
multiple individual binding compounds with low affinities, one can create new 
multicomponent compounds for which the binding avidity is very strong and these 
compounds are therefore specific for expanded polyQ repeats. 
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Figure 5-1. Use of high-avidity multivalent proteins allows for discrimination between short and 
expanded polyQ repeats. While high-affinity monovalent proteins bind strongly to short or to 
expanded polyQ repeats, high-avidity multivalent proteins bind more strongly and specifically to 
expanded polyQ repeats. 
To test this linear lattice theory and derive potential novel therapeutic compounds for 
Huntington’s disease by selecting proteins that bind weakly to a short stretch of polyQ, 
and then assembling together several of these protein building blocks to create a single 
complex containing two to five copies of the polyQ-binding domain. More than 30 
different naturally existing proteins have been engineered for ligand binding, including α-
helical, β-barrel, and β-sandwich proteins [142]. These types of protein domains are 
short peptides that have a simple, thermodynamically stable fold that is able to tolerate 
substitutions of amino acids within the binding surface region. 
We chose to start by using a domain from fibronectin, a large protein that plays an 
essential role in the interaction between cells and the extracellular matrix. The 
fibronectin type III (FN3) domain is a small, independently folded domain that exists 
arranged in tandem repeats within fibronectin and other proteins [143]. The structure of 
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the FN3 domain resembles structures of binding domains of antibodies. Since FN3 
domains naturally exist in a series of repeats with up to 17 FN3 domains in a row, 
their structure is ideally suited to engineering complexes of individual domains 
linked together. Individual FN3 domains are expressed well in bacterial cell culture, are 
very stable under a range of conditions, and have been used previously in selection 
strategies in which mutated FN3 domains that bind a desired protein are selected for 
from a large pool of mutated FN3 domains [144]. 
Figure 5-2. Overview of production of monovalent and multivalent FN3 proteins from 
polyQ-specific FN3 domains. 
Using a pool of FN3 proteins containing a combinatorial library of 108 different FN3 
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domains in which multiple positions have been randomized, proteins were generated 
that bind weakly to soluble polyQ repeats within the first exon of huntingtin. Multiple 
independent binding proteins were linked together to create binding complexes with 
avidity and specificity for the pathogenic, expanded polyQ repeats. 
 
2. Design of High Avidity FN3 Binding Proteins 
2.1. Yeast Display 
The FN3 domain is a protein domain with a beta sandwich structure that can be 
genetically engineered to bind to antigens. Using a library of 108 engineered monomeric 
FN3 domains, yeast display was used to select for FN3 domains with affinity to polyQ. 
The G4 FN3 library was selected as the starting material for our studies [144]. Moderate 
affinity FN3 domains were isolated by magnetic activated cell sorting (MACS) for affinity 
to a synthesized, biotinylated polyQ peptide, K2Q10K2 (Genscript). Three sequential 
rounds of MACS were used to isolate these polyQ-binding domains [145]. FACS was 
subsequently used to select full-length FN3 domains using the C-terminal c-myc tag on 
each of these domains. A streptavidin antibody was used to test for binding of the 
selected yeast to the biotinylated polyQ peptide. 
Plasmid DNA was isolated from the selected population of yeast using a Zymoprep 
yeast plasmid miniprep kit (Zymo Research), with addition of zymolyase to digest the 
yeast cell wall. E. coli (XLI-Blue or XL10-Gold) were transformed and incubated 
overnight. Plasmids DNA was prepared by miniprep and FN3 domains were sequenced 
using pCTCON2 sequencing primers. Sequences were aligned with MegAlign, and the 
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consensus sequences were displayed using WebLogo [146]. Sequencing of 20 clones 
showed an increase in aromatic amino acids in randomized loops above what would be 
expected based on the distribution of amino acids in the unsorted FN3 library. 
 
Figure 5-3. Amino acid distribution in anti-polyQ FN3 (left). Structure of a single FN3 
domain (1FNA) (right). 
 
2.2. Cloning Strategy 
Using the FN3 domains isolated, we produced monovalent and multivalent FN3 proteins 
from polyQ-specific FN3 domains. These FN3 domains were cloned in tandem repeats 
and selected for high avidity to expanded polyQ tracts to create multivalent binding 
agents. The FN3 genes from sorted G4 libraries were subcloned into the pET-24a(+) 
vector (Novagen; San Diego, California, United States) by Gibson assembly (New 
England Biolabs; Ipswich, Massachusetts, United States) (Figure 5-4) [147].  
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Figure 5-4. Multivalent FN3 construct construction. Each FN3 domain was flanked with 
a linker for assembly. 
 
Four to six clones of each were sequenced. The pET-24a(+) vecor encodes a C-terminal 
His6 tag. The FN3 proteins were expressed in E. coli BL21(DE3) cells (Novagen) by 
induction at OD600=0.6-0.8 with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) for 3 to 4 
hours at 37°C. Cells were collected by centrifugation at 6000 x g for 15 min and 
resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 10 
mM imidazole, and 1 mM PMSF). These were sonicated on ice for 4 min. The cell lysate 
was centrifuged at 15,000 x g for 45 min to isolate the soluble fraction. The supernatant 
was incubated with Ni nitriloacetate beads, and the histidine-tagged FN3 domain was 
eluted with 500 mM imidazole. The eluate was concentrated using an Amicon Ultra 
centrifugal filter with a 5 kDa MWCO membrane. The protein was isolated via gel 
filtration on a Superdex 200 HR10/300 or 16/60 column, with yields of 0.5-100 mg/L of 
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bacterial culture. 
While 1-domain FN3 constructs were easily cloned and expressed in bacterial culture, 
cloning of repeated FN3 domains proved to be difficult. Due to similarities between each 
domain, the reactions were easily mis-primed and truncated clones were made. After 
making the linker segments between each FN3 domain significantly longer, up to 5 
tandem domains could be cloned using the method described above. A total of 24 
different constructs were cloned, including thirteen 1-domain, three 2-domain, four 3-
domain, and four 5-domain FN3 constructs. Out of these, six 1-domain, three 2-domain, 
four 3-domain, and two 5-domain FN3 constructs were expressed in cell culture and 
purified. 
The presence of unpaired cysteines in the initial FN3 constructs led to concerns 
regarding oligomerization of FN3 domains during protein purification and analysis. 
Cysteine (TGT/TGC) and histidine (CAT/CAC) were included in the original FN3 library 
at a relatively high frequency due to codon similarity to tyrosine (TAT/TAC), such that 
only 19% of the naïve G4 library was cysteine-free. Several non-cysteine-containing FN3 
constructs have been cloned, expressed, and purified. Additionally, because purification 
of multi-domain FN3 constructs has produced only small amounts of pure protein, 
purification techniques must be optimized to increase the production of multi-domain 
FN3 constructs and decrease the amount of non-specific binding of FN3 domains to 
other components in the cell lysate. Possible methods to optimize multi-domain FN3 
constructs include alternate cloning methods and expression in yeast. 
2.3. Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is a phenomenon that occurs when polarized light, 
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under conditions of total internal reflection, hits a layer of gold at the interface between a 
glass sensor surface, which has high refractive index, and a buffer, which has low 
refractive index. The change in refractive index in the buffer close to the gold layer can 
be detected, and thereby yield information about the interaction between proteins 
immobilized on the sensor surface and molecules in the buffer. SPR can be used to 
determine the strength of binding of an interaction, KD. In our experiments, huntingtin 
with 16 glutamines (HD-16Q) was immobilized on Biacore chips using amino coupling, 
and FN3 constructs were injected through flow cells over the surface at successive 
dilutions to obtain the binding constants. A control antibody, MW1, which is known to 
bind to the polyQ repeat in huntingtin exon 1, was also used in this experiment. 
 
Figure 5-5. SPR results demonstrate micromolar binding affinity of monomeric FN3 
domain (FN3-1) to HD-16Q, but increasing affinity with two (2-Domain FN3) and three 
(3-Domain FN3) linked FN3 domains. MW1 is an anti-polyQ antibody that acted as a 
control for this experiment. 
   
 
104
Results demonstrated that there was micromolar binding affinity to a 1-domain FN3 
construct, as expected. Additionally, a 2-domain FN3 construct bound with a stronger 
affinity to HD-16Q. Future experiments will be aimed at careful observation of the effect 
of the newly purified non-cysteine-containing anti-polyQ FN3s on the biochemical 
features of huntingtin. 
 
3. Future of Therapeutics for Huntington’s Disease 
Although 20 years have passed since the discovery of the Huntington’s disease gene, 
Huntington’s disease remains without a cure or even effective treatment. Current 
medications for treatment of HD include medications for movement disorders, such as 
antipsychotic drugs, and medications for psychiatric disorders, such as antidepressants 
and mood-stabilizing drugs. Three HD clinical trials are currently underway in the United 
States: Enroll-HD, a study to accelerate development of therapies for HD by compiling 
clinical data and biological samples during the “natural course” of the disease; 2CARE, a 
test of Coenzyme Q10; and CREST-E, a test of creatine. However, no treatment is 
available to slow or stop the progressive course of the disease. Creating multivalent 
binding proteins with high avidity and specificity for the expanded polyQ tracts that cause 
Huntington’s disease may be a key to inhibition of aggregation of polyQ and have 
implications for future targeted treatments for Huntington’s disease. 
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